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ABSTRACT 
ENDOGENOUS GENE TAGGING OF PFR2 AND PFR5 IN TRYPANOSOMA 
CRUZI USING CRISPR/CAS9 
by 
Naomi Nicole Bryant 
August 2019 
The flagellum of Trypanosoma cruzi contains the paraflagellar rod (PFR) an 
extra-axonemal scaffolding. The PFR consists of a lattice of cytoskeletal filaments that 
lies alongside the (9 + 2) microtubular axoneme, beginning at the flagellar pocket and 
extending to the flagellar tip. The PFR has only been observed within the phylums 
Euglenozoa and Dinoflagellata, although many eukaryotic organisms with long flagella 
have extra-axonemal structures that accommodate enzymes and regulatory proteins along 
with serving as scaffolding. The exact function and basic molecular composition of the 
PFR has yet to be determined although the major structural components, PFR1 and PFR2 
and several minor proteins have been identified. The PFR is not only a complex structure 
that has been shown to be critical for motility, it also constitutes a unique set of proteins 
that are known to be immunogenic and provide protective immunity to T. cruzi.  PFR5, a 
hypothetical minor component of the PFR, contains a PFR internal domain and an SH3 
binding domain. Currently, it is unknown if the protein product of pfr5 localizes to the 
flagellum. We have adapted a CRISPR/Cas9 endogenous gene tagging protocol to tag 
pfr5 and investigate the subcellular localization of the protein. PFR2 localization serves 
as a proof of principle for this system as localization is well established. This technique 
allows for the precise insertion of a small 3x hemagglutinin tag at the C-terminus of the 
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gene of interest, with subsequent protein product also containing the tag. Localization of 
the tagged proteins is can then be visualized using immunofluorescence. Successful 
utilization of this technique, as well as localization of PFR5, will contribute to further the 
research and understanding of this unique structure.  
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        CHAPTER I 
INTRODUCTION 
 Trypanosoma cruzi, the causative agent of Chagas disease, is currently estimated 
to infect 8 million people worldwide and cause 10,000 deaths per year (WHO, 2019-A). 
Treatments for Chagas disease are limited to benznidazole or nifurtimox, with varying 
efficacy rates due to stage of disease and drug resistance (Sales Junior et al., 2017). Due 
to these efficacy rates, the search for new drugs as well as vaccinations is heightened. 
Currently, there is no vaccination for Chagas, but several vaccine targets have been found 
over years of research. One such target is the paraflagellar rod (PFR), which is an extra-
axonemal structure composed of cytoskeletal filaments that extends from the flagellar 
pocket to the tip of the flagellum (Portman and Gull, 2010). The proteins of PFR make 
good vaccine targets as they are highly conserved among strains of T. cruzi, are not 
homologous to human proteins, and are immunogenic (Clark et al., 2005). Immunization 
with purified PFR proteins as well as recombinant PFR has shown to provide immunity 
against T. cruzi, in mice (Wrightsman et al., 1995). 
The protein composition of the PFR is not fully known although research has 
revealed a core set of proteins that make up the PFR family (PFR1, PFR2, PAR1, and 
PAR4); all of these proteins, except PAR4, share a highly conserved 32aa region known 
as the PFR domain (Clark et al., 2005).  Since the discovery of this family new proteins 
with a PFR domain have been discovered. PFR5 and PFR6 are among those discovered, 
with PFR5 having an additional SH3 binding domain, which has not been seen in any of 
the other PFR proteins (Clark et al., 2005). It has yet to be confirmed if these proteins do 
localize to the PFR.   
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The purpose of this study is to determine the localization of PFR5 utilizing a new 
technique, in T. cruzi, for protein localization. Currently, the most common methods for 
protein localization in T. cruzi are monoclonal antibodies and overexpression of tagged 
proteins. Both methods have been used to successfully locate proteins in T. cruzi, but 
they do have their drawbacks. Monoclonal antibodies can be cross reactive if the protein 
of interest is homologous in sequence to other proteins within the organism (Lander et al., 
2016). Protein overexpression can in some cases lead to toxicity or inaccurate 
interpretation of results due to the high levels of protein produced and improper folding 
(Moriya, 2015). Due to these potential drawback’s researchers have been pushing 
towards the use of CRISPR/Cas9 technology to tag genes endogenously.  
Lander et al. (2016) developed one of the first protocols for C-terminal gene 
tagging in T. cruzi using CRISPR/Cas9. This protocol uses a gene specific sgRNA/Cas9 
plasmid and donor DNA cassette to induce homology driven repair and insertion of a 
small 3x hemagglutinin tag (Lander et al., 2016). Subsequent protein product of the gene 
can then be localized using a hemagglutinin specific fluorescently conjugated antibody. 
In this study, we utilized this protocol to look at localization of PFR5 and PFR2, with 
PFR2 functioning as a proof of principle.  
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CHAPTER II 
LITERATURE REVIEW 
Discovery of T. cruzi 
Trypanosoma cruzi was initially identified by Carlos Chagas in 1908 during an 
anti-malaria campaign for the Central do Brasil Railroad (Kropf and Sa, 2009). During 
the campaign Chagas set up a small laboratory in the rural settlement of Lassance. It was 
within Lassance that Chagas was made aware of a hematophagous insect that was known 
to frequently bite the faces of the local people (Kropf and Sa, 2009). Due to his previous 
knowledge of vector transmission, Chagas speculated that these insects may harbor a 
pathogen that could be transmitted to humans. Dissection of these insects revealed a 
flagellated protozoan, more specifically a trypanosome, within the hindgut (Kropf and Sa, 
2009). In order to determine if this trypanosome could infect a mammalian host, Chagas 
sent several of the insects to his mentor Oswaldo Cruz, who exposed lab-bred marmosets 
to the insects (Kropf and Sa, 2009). Of those marmosets that became ill after exposure, 
Cruz found a form of the trypanosome within the blood (Kropf and Sa, 2009). Chagas 
soon after realized that this was a new species of trypanosome and named it T. cruzi, after 
his mentor Oswaldo Cruz (Kropf and Sa, 2009). 
Suspecting that humans could be hosts to T. cruzi, Chagas began screening the 
people of Lassance for the parasite. On April 14, 1909, Chagas came across a feverish 
two-year-old girl with enlarged lymph nodes, liver, and spleen (Kropf and Sa, 2009). 
Subsequent testing of her blood revealed the presence of T. cruzi. Due to the presence of 
the parasite and the similarity of the child’s symptoms to that of previous animal 
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research, Chagas concluded that this was the first case of a new disease, that would go on 
to be called Chagas disease (Kropf and Sa, 2009).  
Although Chagas is the most prominent figure in regard to T. cruzi, he is not the 
only one to have contributed to its early identification and characterization, with some of 
the more notable contributors being Stanislaus Von Prowazek, Gaspar de Oliveira, and 
Alexandre Joseph Emile Brumpt (Steverding, 2014). Of the three individuals Prowazek, a 
Czechoslovakian zoologist and parasitologist, is the most acknowledged by Chagas 
himself, with Chagas publicly stating that his work on T. cruzi’s life cycle within the 
intermediate host was done under his guidance (Kropf and Sa, 2009). Vianna, a Brazilian 
pathologist, described the presence of the intracellular form (amastigote) of T. cruzi 
within skeletal and heart muscle cells (Steverding, 2014). Brumpt, a French pathologist, 
established that the mechanism of vector transmission was through getting insect feces in 
the bite wound rather than the bite itself (Steverding, 2014). Since the initial 
identification of T. cruzi in the early 1900s research has continued to expand on the ideas 
set forth by Chagas and fellow scientists. 
Morphology and Life Cycle 
Throughout its life cycle T. cruzi takes on several distinct morphological forms 
(amastigote, epimastigote, and trypomastigote) within the insect and mammalian host. 
These forms can be easily identified by the position of the kinetoplast (modified 
mitochondria which houses its own DNA known as kDNA) relative to where the 
flagellum emerges. Amastigotes are the smallest of the three forms (25μm X 2μm) and 
reside within the cytoplasm of mammalian host cells (de Lana et al., 2010). Their 
kinetoplast is situated in the center of the cellular body, anterior to the nucleus and 
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posterior to the base the short flagellum (figure 1). Amastigotes are the only form with a 
flagellum that does not extend out of the cellular body. Epimastigotes (20-40μm) are 
found within the intestine of the insect vector with their kinetoplast situated similarly to 
amastigotes, but unlike amastigotes, they have a flagellum that originates anteriorly of the 
nucleus and extends down past the cellular body (figure 1) (de Lana et al., 2010). 
Trypomastigotes (17μm) are the form infectious to both the insect vector and the 
mammalian host and reside in either the feces of the insect or the blood stream of the host 
(Martins et al., 2012). Their kinetoplast is situated at the most posterior end of the 
parasite, at the base of the flagellum. The flagellum originates posteriorly of the nucleus 
and extends anteriorly past the cellular body (figure 1).  
 
 
Figure 1 Illustration of the morphological forms of T. cruzi, including the location of 
the kinetoplast, nucleus, and flagellum (Modified from Wheeler, 2011).  
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The life cycle of T. cruzi begins with an infected Triatomine bug. These insects 
typically come out at night to take blood meals and are attracted to CO2. Due to this 
attraction, they often bite near the face, thus earning their nickname the kissing bug. 
While taking a blood meal these insects will often defecate in order to make room for the 
incoming blood meal. Within the feces, is where the infectious form of the parasite, the 
metacyclic trypomastigote, resides. When the feces comes in contact with the bite wound 
or a mucosal membrane, typically through scratching the bite site, the trypomastigotes 
will enter the cells at the site of infection. Once inside the trypomastigotes will transform 
into amastigotes, as the trypomastigote form is the only form unable to go through 
replication. The amastigotes will then go through several rounds of replication via binary 
fission, before transforming back into trypomastigotes and rupturing from the cell. The 
newly released trypomastigotes will then go on to infect neighboring cells or travel 
through the bloodstream to other parts of the body. When a kissing bug takes a blood 
meal from an infected individual, they will take up trypomastigotes traveling through the 
bloodstream. Within the intestinal tract of the insect, the trypomastigotes transform into 
epimastigotes and replicate via binary fission. As the epimastigotes move towards the 
rectum, they transform into metacyclic trypomastigotes that are released with the feces. 
In addition to its unique life cycle and morphological forms, T. cruzi also has 
several structures that differentiate it from other eukaryotes. One such structure is the 
paraflagellar rod (PFR). The PFR is a lattice structure of cytoskeletal filaments that lies 
along the (9+2) microtubular axoneme and extends from the flagellar pocket to the tip of 
the flagellum (figure 2) (Portman and Gull, 2010). The exact structural organization and 
protein makeup of the PFR is not fully understood although research has provided insight 
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on the general organization of the filaments as well as some of the major proteins. The 
filaments are arranged in a trilaminar manner with proximal, intermediate, and distal 
layers (Portman and Gull, 2010). The proximal and distal layers share similar overall 
structure with plates that contain thick (25nm) and thin (7nm) filaments that cross one 
another at 100° angles, the proximal layer contains two plates while the distal contains 11 
(Farina et al., 1986). The intermediate layer is composed mainly of thin filaments which 
connect the proximal and distal layers (Farina et al., 1986). The PFR is attached to the 
microtubule axoneme though 4-7 electron dense filaments that connect the proximal 
domain to doublets 4 and 7 in the axoneme (Farina et al., 1986).  
 
Along with the identification of the distinct layers, a core set of proteins (PFR1, 
PFR2, PAR1, and PAR4) belonging to the PFR family have also been identified. Most of 
the protein within this family share a highly conserved 32 amino acid region known as 
the PFR domain (Clark et al. 2005). Of the proteins within the family, PFR1 and PFR2 
were the first two to be discovered. PFR1 and PFR2 were initially identified during a 
Figure 2 Illustration showing the location of the paraflagellar rod within the flagellum 
(Wheeler, 2006). 
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study that compared purified flagellar proteins of an organism with a PFR (Euglena 
gracilis) to one without (Chlamydomonas reinhardtii) (Hyams, 1982). SDS-PAGE 
analysis of the purified proteins revealed two proteins, at 80 kDa (PFR1) and 69 kDa 
(PFR2), which were present within E. gracilis and not in C. reinhardtii (Hyams, 1982). 
Proof of these proteins’ association with the PFR came in a later study that showed that 
PFR enriched flagellar preparations were predominantly composed of PFR1 and PFR2, 
due to the presence of the two bands seen during SDS-PAGE (Cunha et al., 1984). 
Subsequent research by Fouts et al. (1998) provided more insight into the proteins within 
these bands and revealed that each band actually contained two proteins instead of one; 
one band containing PFR1 and PAR1, and the other PFR2 and PAR4. Fouts et al. (1998) 
also provide proof of PFR localization for PAR1, PAR4, and PFR1 in T. cruzi using 
immunofluorescence. Since the initial discovery of the four core proteins two other 
proteins, PFR5 and PFR6, thought to belong to the PFR family have been discovered. In 
a study done by Clark et al. (2005), researchers searched sequence databases for 
sequences containing PFR domains. What the researchers found were two proteins, 
designated PFR5 and PFR6, with PFR5 found to have the additional motif of an SH3 
binding domain (Clark et al., 2005). Since their initial discovery, it is unknown if these 
proteins localize to the PFR, as their family grouping would suggests, and if they do 
where within the PFR they are.  
In regard to the function of the PFR, like the organization, it is not fully known 
but one function has become apparent over years of research. The PFR seems to function 
as support structure for the flagellum, aiding in motility.  Several research studies have 
shown that removal of certain PFR proteins lead to decreased motility. One such study 
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done by Lander et al. (2015) found that CRISPR mediated knockout pfr1 and pfr2 in T. 
cruzi lead to improper formation of the PFR and detachment of the axoneme from the cell 
body. The consequence of this improper formation was paralysis of the organism, 
indicating PFRs strong role in motility.  
Epidemiology 
 T. cruzi has three main cycles of transmission, sylvatic (wild), peridomestic, and 
domestic. In the sylvatic cycle, species of the Triatomine subfamily (mainly Triatoma 
spp., Rhodnius prolixus, and Panstronglus megistus), transmit T. cruzi among over 100 
mammalian species from eight orders (Marsupilia, Xenarthra, Rodentia, Primata, 
Carnivora, Chiroptera, and Artiodactyla) in the Americas and southern US (Jansen and 
Roque, 2010; Bern et al., 2011). Mammals are the only sylvatic host for T. cruzi as birds, 
reptiles, and amphibians are unable to maintain the life cycle due to complement factors 
in their blood that trypomastigotes are unable to combat (Jansen and Roque, 2010). 
Mechanisms of transmission in the sylvatic cycle include contamination of the bite 
wound with infectious feces following blood meal from triatomine, ingestion of infected 
triatomine (seen with the omnivorous mammals), and ingestion of prey infected with T. 
cruzi (seen with carnivores) (Jansen and Roque, 2010). Infection via fecal contamination 
follows the traditional life cycle of T. cruzi while ingestion changes the initial infection 
from one that originates at the skin to one that starts in the gastrointestinal tract.    
 The peridomestic and domestic cycles both involve domestic animals (cats, dogs, 
pigs, sheep, goats, etc.) but differ in how they are maintained (Bezerra et al., 2014). The 
peridomestic cycle originated from the slyvatic cycle but now involves the transmission 
of T. cruzi among domesticated animals in a fashion similar to the slyvatic (Coura and 
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Dias, 2009). The domestic cycle involves the transmission of T. cruzi between humans 
and domesticated animals through domesticated triatomine (Coura and Dias, 2009). 
These triatomine differ from the sylvatic in that they have become accustomed to living 
within and around human dwellings; T. infestans, T. dimidiate, and R. prolixus are the 
most often associated with the domestic cycle (Breniere et al., 2010). The types of 
dwellings associated with domestic triatomine are seen in poor or rural areas, and often 
have mud walls and thatched roofing. This type of housing provides triatomine with 
ample spots to hide in during the day. Domestic triatomines propensity to live in poor 
dwellings is the main driver behind the geographic distribution of Chagas disease and the 
number of cases seen. Chagas disease is predominately found in Latin America where the 
vector is found, with imported cases also showing up in the US, Canada, and Europe; the 
US has an estimate 300,000 individuals with Chagas (CDC, 2019-A). The main mode of 
transmission in endemic areas involves vector transmission, with the contamination of the 
bite wound or mucosal membrane with infectious feces. Other modes of transmission that 
account for a small portion of cases are congenital (from infected mother to newborn), 
blood transfusion, organ transplant, and contaminated food/beverage (usually 
contaminated with infectious triatomine feces) (CDC, 2019-A). Methods to curb the 
domestic cycle of T. cruzi have focused mainly on vector transmission and blood 
transfusions, with many endemic areas implementing vector control methods (pesticides 
and home improvements) and blood screening protocols (WHO, 2019-B)    
Clinical Manifestation 
 Chagas disease presents itself in two main phases, acute and chronic. The acute 
phase begins shortly (1-2 weeks) after initial infection with T. cruzi and typically lasts 4-
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8 weeks (Bern et al., 2011). During this time most infected individuals will either have 
mild symptoms, such as a fever and swollen lymph nodes or remain asymptomatic. In 
some cases, individuals can present with more prominent or severe symptoms. The 
symptoms can be a combination of fever, headache, fatigue, swelling at the site of 
infection (Romana’s sign for the eyelid or chagoma for the skin), enlarged spleen/liver, 
swollen lymph nodes or cardiac/neurological alterations (Rassi et al., 2010). Death can 
occur in the acute phase but is uncommon and most often due to inflammation of the 
heart/brain (Rassi et al., 2010). Due to most infected individuals being asymptomatic or 
having non-specific symptoms many go undiagnosed. For those who have a clinical 
presentation (often Romana’s or chargoma) or suspect they have been infected, blood 
smears and Polymerase chain reactions (PCR) tests can be used to confirm infection, due 
to the high levels of parasitemia seen during this phase (Bern et. al, 2011).  
 Treatment for acute Chagas comes in the form of two antitrypanosomal drugs, 
nifurtimox and benznidazole. Nifurtimox was the first drug ever used to treat Chagas and 
has a cure rate 88-100% for individuals who complete the full course of treatment during 
the acute phase (8-10mg/kg 4 times a day for 90 days) (Sales et al., 2017; CDC, 2019-B). 
Side effects most commonly associated with nifurtimox include nausea, vomiting, weight 
loss, tingling of the extremities, and drowsiness (Sales et al., 2017). Currently, 
nirfurtimox is not the recommended course of treatment and is no longer used in endemic 
areas, due to its tendency to produce more severe side effects than its counterpart (Sales 
et al., 2017). Benznidazole, the preferred drug, has a cure rate of around 80% following 
completion of the treatment in the acute phase (5-8mg/kg twice a day for 60 days) (Sales 
et al., 2017; CDC, 2019-B). The most common side effects are tingling of the extremities, 
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nerve pain, and weight loss (Sales et al., 2017). Due to the symptoms, both treatments can 
cause many individuals to either have gaps in their treatment or not finish. 
 For those who do not receive or finish treatment during the acute phase, they will 
enter the indeterminate chronic phase. This phase begins two to three months after initial 
infection and is characterized by continuous low levels of circulating parasite (Rassi et 
al., 2010). Individuals within this phase are asymptomatic and can remain so for the rest 
of their life. In some cases, indeterminate individuals will enter the chronic phase, which 
occurs 20-30 years after initial infection and is characterized by two complications. 20-
30% of indeterminate individuals will go on to develop cardiac complications such as 
heart failure, irregular heartbeats, or the formation of blood clots (WHO, 2019-B; Rassi et 
al., 2010). 10% of individuals will go on to develop digestive complications which can 
manifest in dilatation of the colon or esophagus, termed megacolon or megaesophagus 
(WHO, 2019-B). Diagnosis of chronic Chagas cannot be made using blood smears, like 
in acute, since parasite levels are low, instead serological techniques like ELISA, or PCR 
tests are used (Bern et al., 2010). Treatment of chronic Chagas is more about symptom 
management as the drugs available in the acute phase are not curative for the chronic 
phase. Although not curative benznidazole has been shown to slow the progression of 
cardiac complications in some chronic individuals (Sales et al., 2017).   
Immune Response and Evasion 
Host Cell Entry 
 Following entry through the bite wound or mucosal membrane, metacyclic 
trypomastiogotes will enter either the cells of the tissue (ex. fibroblasts) or innate immune 
system (ex. macrophage) (Truyens and Carlier, 2010). Cells of the tissue are 
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preferentially infected at the start of infection due to the parasites limited ability to 
migrate to draining lymph nodes and its desire to stave off recognition by the immune 
system (Padilla et al., 2009). Entry into non-phagocytic cells follows one of two routes: 
lysosome dependent or invagination of the cell membrane with subsequent lysosomal 
fusion (Cardoso et al. 2015). Regardless of which pathway is chosen, host cell entry 
begins with the binding of T. cruzi glycosylphosphatidylinositol (GPI) surface proteins to 
their receptor on the host cell (de Pablos and Osuna, 2012; Bartholomeu et al., 2014). 
Binding of GPI initiates the PI3K pathway, which results in the release of Ca2+ in the host 
cell (Rodriguez et al., 1995). The lysosome dependent route utilizes this increase Ca2+ to 
drive lysosomes to the cell membrane (Rodriguez et al., 1996). Fusion of the lysosomes 
with the cell membrane allows the parasite to enter the cell through an acidic 
parasitophorous vacuole (vacuole containing a parasite). The invagination route utilizes 
the PI3K pathway by entering the cell membrane in a region that is rich with 
phsohatidlylinositol trisphosphate (PIP3), resulting in the formation of a parasitophorous 
vacuole (Woolsey et al., 2003). The vacuole goes on to fuse with early endosomes and 
then lysosomes, resulting in the same acidic vacuole as the lysosome dependent route 
(Woolsey et al., 2003).  
 The acidification of the parasitophorous vacuole does not harm the trypomastigote 
rather it aids in its transition to amastigote and exit from the vacuole. The internal 
membrane of the vacuole is composed mainly to two sialylated proteins, lysosome-
associated membrane proteins (LAMP) 1 and 2, which help to prevent destruction of the 
vacuole (Kornfeld and Mellman, 1989; Hall et al., 1992; Alberetti et al., 2010). T. cruzi, 
on its surface, has trans-sialidase which in conditions of low pH will release from 
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parasite and become active (Cardoso et al., 2015). The active trans-sialidase remove 
sialic acid from LAMP 1 and 2 and transfer them to the surface on the parasite (Albertti 
et al., 2010; Hall et al., 1992). The removal of sialic acid causes the vacuole to become 
susceptible to pore-forming proteins which cause the vacuole to lyse, allowing 
amastigotes to enter the cytosol and begin replication (Andrews et al., 1990).  
Innate Immune Response 
  Macrophages present in the tissue at the time of infection are the first immune 
cells to come in contact with T. cruzi. In order to recognize T. cruzi and initiate an 
immune response, macrophages have membrane bound receptors known as toll like 
receptors (TLRs), on the surface of the cell and within endosomes (Acevedo et al., 2018). 
These TLRs detect pathogens through the recognition of pathogen associate molecular 
patterns (PAMPs). When T. cruzi encounters the surface of a macrophage they activate 
TLR2/6 and 4; TLR2/6 recognize GPI while TLR4 recognizes 
glycoinositolphospholipids (GIPLs) (Junqueria et al., 2010; Oliveira et al., 2004; Campos 
et al., 2001). When T. cruzi enters macrophages through phagocytosis, they activate 
TLR7 and 9 within the parasitophorous vacuole, which recognize parasite RNA and 
DNA respectively (Bafica et al., 2006; Caetano et al., 2011). Activation of a TLR 
initiates the Myd88 pathway, in the case of TLR2/6, 4, 7, and 9, and the TRIFF pathway 
in the case of TLR4 (Truyens and Carlier, 2010; Rodrigues et al., 2012). The Myd88 
pathway leads to the production of the pro-inflammatory cytokines TNFα (only produced 
by TLR2/6 activation) and IL-12, while the TRIFF pathway produces the type-1 
interferons INFα/β (Trinchieri and Sher, 2007; Rodrigues et al., 2012). Production of 
these cytokines and interferons initiate the innate immune response to T. cruzi, 
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specifically: TNFα permeabilizes the blood vessels allowing immune cells to enter the 
site of infection, IL-12 brings natural killer (NK) cells to the site of infection and 
activates them, and INFα/β increases expression of NK receptor ligands while also 
activating NK cells. Activated NK cells will release IFNγ, activating macrophages and 
increasing their propensity for phagocytosis. Production of pro-inflammatory cytokines 
also induces the production of nitric oxide within the parasitophorous vacuole (Munoz-
Fernandez et al., 1992). Nitric oxide (NO) functions to kill T. cruzi by inhibiting vital 
cystine rich proteins, like cruzipain, or producing peroxynitrite which decreases 
membrane integrity and induces apoptosis by impairing mitochondrial function (Radi, 
2013; Venturini et al., 2000; Alvarez et al., 2011). To combat oxides produced by 
macrophages T. cruzi has peroxidases that detoxify the vacuole (Piacenza et al., 2008).    
 T. cruzi, specifically trypomastigotes, are exposed to another aspect of the innate 
immune system after they rupture from a host cell and travel to the bloodstream. Within 
the bloodstream, there are proteins for three complement pathways (alternative, lectin, 
and classical) which all work to tag pathogens for opsonization, recruit immune cells, and 
perforate cell membranes. Each pathway is activated in a different manner before 
converging in the formation of C3 convertase. The alternative pathway is activated when 
C3 is spontaneously cleaved into C3b and attached to the surface of the parasite. Binding 
of C3b initiates the formation of C3 convertase. The lectin pathway is activated by the 
binding of mannose-binding lectin and ficolins to N-glycans (Cestari et al., 2009). This 
complex cleaves C4 and C2 to form the C3 convertase. The classical pathway is activated 
by the binding of T. cruzi specific antibodies and C1. C1 cleaves both C4 and C2 to form 
C3 convertase. In order to combat either the activation of a pathway or the formation of 
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C3 convertase T. cruzi has several molecules on its surface, calreticulin (TcCRT), T. 
cruzi complement C2 receptor inhibitor trispanning (TcCRIT), T. cruzi complement 
regulatory protein (TcCRP), and trypomastigote decay acceleration factor (T-DAF). 
TcCRT inhibits activation of the lectin and classical pathway by inhibiting the function of 
mannose-binding lectin and C1 (Ferreira et al., 2004; Sosoniuk et al., 2014). TcCRIT 
functions by inhibiting the formation of C3 convertase, in the classical pathway, through 
competing with C4 in binding to C2 (Cestari et al., 2008, 2009). TcCRP inhibits the 
formation of C3 conversate in all three pathways by binding either C3b or C4b (Lidani et 
al., 2017; Norris et al., 1991). Lastly, T-DAF interferes with the overall formation of the 
C3 convertase in the alternative, classical, and possibly the lectin pathways (Joiner et al., 
1988; Tambourgi et al., 1993).   
Adaptive Immune Response 
 The move from innate to adaptive immunity comes with the migration of 
dendritic cells from infected tissue to the lymph nodes. Within the tissue dendritic cells 
function similarly to macrophages in that they readily phagocytose parasites, which 
activate TLRs and lead to production of pro-inflammatory cytokines. Where dendritic 
cells differ from macrophage is in the purpose for up taking parasites. Instead of trying to 
clear the immediate infection, dendritic cells prioritize processing T. cruzi antigen so that 
it can be presented on the cell surface via major histocompatibility complexes (MHC) 
class I and II to cell of adaptive immunity. MHCs class I is present on most cells within 
the body while MHC class II is present only on professional antigen presenting cells 
including dendritic cells, B cells, macrophage, and T cells. During their migration to the 
lymph nodes, dendritic cells undergo a maturation process where they increase 
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expression of MHC class II, costimulatory molecules (CD40, CD80, and CD86) that aid 
in T cell activation, and pro-inflammatory cytokines (Van Overtvelt et al., 1999). T. cruzi 
can inhibit this process by downregulating IL-12, TNFα, CD40 and MHC class II, thus 
delaying the start of adaptive immunity (Overtvelt et al., 1999).  
 Once mature dendritic cells reach the lymph nodes CD8 T cells are first activated 
through binding of MHC class I on dendritic cells (Truyens and Carlier, 2010). Following 
activation, CD8 T cells leave the lymph node and search for cells infected with T. cruzi. 
Identification of infected cells is done through the binding of the T cell receptor to an 
MHC class I complex that contains antigen for T. cruzi. Successful binding results in 
release of cytotoxic granules which kill the infected cells as well as the release IFNγ to 
increase antigen presentation and macrophage activation. Back in the lymph node, 
dendritic cells are also activating CD4 T cells through MHC class II. Activated CD4 T 
cells can either help in the activation of CD8 T cells through binding of MHC class II on 
CD8 T cells or leave the lymph node in search for infected macrophage. Once infected 
macrophage are located through binding of MHC class II, CD4 T cells release IFNγ to 
activate macrophage and induce killing of the parasites within the parasitophorous 
vacuoles. Returning to the lymph node again B cells with T. cruzi specific antibody are 
also being activated with the help of T follicular helper (TFH) cells. Activation occurs 
through the binding of MHC class II on the B cells and release of cytokines by the TFH, 
which cause the B cells to differentiate into a plasma cell and begin releasing antibodies. 
The goal of these antibodies is to tag extracellular T. cruzi for opsonization. 
  Collectively all of the mechanisms used to target T. cruzi during the adaptive 
immune response do little to fully clear the infection. This is due to the mechanisms T. 
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cruzi has developed to diminish the effectiveness of effector cells. One method by which 
T. cruzi does is through the presentation of highly variable antigens, which increases the 
time it takes find an antigen the works to effectively target T. cruzi. (Truyens and Carlier, 
2010). This results in the production of polyclonal antibodies and T cells that are 
essentially non-functional is this system. In addition, some of these antigens do not 
stimulate a strong proliferative response in T or B cells thus limiting the population of 
effector cells (Truyens and Carlier, 2010). Another way in which T. cruzi limits the 
population of effector cells is through the release of active trans-sialidase. These active 
sialidase can bind mucin on the surface of lymphocytes and induce apoptosis, decreasing 
cell populations (Mucci et al., 2002). Lymphocyte apoptosis can also result from the high 
levels of NO and TNFα produced during the immune response to T. cruzi (Truyens and 
Carlier, 2010). The cell debris created also aids in the suppression of the immune 
response through the production of TGFβ, which suppresses macrophage activation and T 
cell function, following phagocytosis (Truyens and Carlier, 2010).   
Paraflagellar Rod Immunogenicity 
PFR’s immunogenic properties were initially identified in a study that immunized 
mice with cell factions from epimastigotes and then challenged them with a lethal dose of 
trypomastigotes (Segura et al., 1976). Of the cell fractions used the flagellar fraction was 
the most effective, with 90% of the mice surviving compared to the 0-50% seen with the 
other fractions (Segura et al., 1976). This study showed the ability of the flagellum to be 
protective in an acute infection scenario, but not in a chronic. Building on these results 
another study immunized mice with similar cell fractions but challenged with a lower 
dose of trypomastigotes (Ruiz et al., 1985). What they found, like the previous study, was 
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that the flagellar faction was the most effective. Mice that were immunized with the 
purified flagellar fraction had fewer instances of positive xenodiagnoses (feeding blood 
to the insect vector and the checking the vector for parasites) and showed no signs of 
heart inflammation (potential complication of chronic Chagas disease) (Ruiz et al., 1985).  
Following the positive results seen with the flagellar fraction, researchers 
investigated the proteins of the flagellum to find possible antigens that could be used in a 
vaccine. The proteins of the PFR became of interest due to the PFR being a unique 
structure found only in the Euglenids and Kinetoplasts. The first study to look at the PFR 
as a source of antigen, isolated PAR1 and PFR2 for immunization of mice with 
subsequent lethal challenge (Wrightsman et al., 1995). What this study found was that 
mice immunized subcutaneously survived (100%) lethal challenge, while mice 
immunized intraperitoneally did not (Wrightsman et al., 1995). In addition, both 
vaccination methods produced antibodies specific PAR1 and PFR2, with intraperitoneal 
producing significantly more (Wrightsman et al., 1995). The significant difference in 
survival post challenge provided the first hint that immunity towards T. cruzi may not be 
mediated by antibodies. Instead, one study by Miller et al. (1997) concluded that 
immunity following immunization with PFR was mediated by CD4 and CD8 T cells, and 
did not require antibodies. This conclusion was founded, in part, by immunizing mice 
either genetically deficient in B cells or MHC class 1, or depleted of CD4 T cells and 
challenging them with a lethal dose of T. cruzi trypomastigotes (Miller et al., 1997). The 
results of the B cell and MHC class 1 experiments were reported as parasitemia and 
number of survivors, with the B cell deficient mice having reduced parasitemia and 100% 
survival, and the MHC class 1 deficient mice having increased parasitemia and 0% 
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survival 20 days post challenge (Miller et al. 1997). Both of these results enforce the 
conclusion that T cells rather than B cells are required for T. cruzi immunity. The results 
of the CD4 T cell depleted mice were more focused on parasitemia post challenge, as all 
of the PFR immunized mice survived, unlike the MHC class 1 deficient mice (Miller et 
al., 1997). The parasitemia of the immunized mice remained at constant high for 80 days 
post challenge, only decreasing once CD4 T cell populations were allowed to regrow 
(Miller et al., 1997). These results show that CD4 and CD8 T cells are required for 
complete immunity with CD8 T cells being critical for survival and CD4 T cells being 
critical for parasite clearance. In addition to looking at the overall importance of immune 
cells, macrophage activation by IFNγ production was explored through in vitro 
experiments using T cells from immunized mice and the immunization and subsequent 
challenge of mice genetically deficient in IFNγ (Miller et al., 1997). The results of the in 
vitro experiments showed that CD4 T cells from immunized mice produced high levels of 
IFNγ in comparison to CD8 and naïve T cells (Miller et al., 1997). The results of the in 
vivo study showed that mice deficient in IFNγ were unable to survive past 19 days post 
infection due to increased levels of parasitemia, which were higher than those seen in the 
other genetically deficient mice (Miller at al., 1997). Both the in vitro and in vivo studies 
indicate the importance of CD4 T cells and their production of IFN-γ in T. cruzi 
immunity and clearance.      
 The mechanism by which PFR primed CD4 and CD8 T cells are able to recognize 
infected cells starts with T. cruzi entering the vacuole of a cell and beginning its transition 
from trypomastigote to amastigote. During this transition, the parasite will duplicate its 
kinetoplast and flagellum before going through cytokinesis (Kurup and Tarelton, 2014). 
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This results in one daughter cell having a nucleus, kinetoplast, and shortened flagellum 
(characteristic of amastigotes), while the other has no nucleus, a kinetoplast, and the 
longer original flagellum (Kurup and Tarelton, 2014). The reason for this uneven division 
is thought to be the result of the long flagellum being too difficult for the parasite to 
absorb or dissolve, so it disposes of it (Kurup and Tarleton, 2014). Following the 
division, the vacuole dissolves and the daughter cells are released into the cytoplasm 
(Kurup and Tarelton, 2014). The amastigote goes on to replicate while the other daughter 
cell is transported to the proteasome where it is degraded (Kurup and Tarelton, 2014). 
The degraded remnants are then either transported to the endoplasmic reticulum, where 
they are loaded into MHC class 1 or they are transported to vesicles containing MHC 
class 2.  
This mechanism of disposing of the flagellum allows for the proteins of the PFR 
to be some of the first T. cruzi antigens presented to CD4 and CD8 T cells (Kurup and 
Tarelton, 2014). Activated CD4 T cells release IFN-γ, which activates macrophages by 
increasing phagocytosis and production of nitric oxide (Miller et al., 1997). Activated 
CD8 T cells can also release IFN-γ, although at a lower rate than CD4 T cells, in addition 
to the release of granzymes which initiate death of an infected host cell (Kurup and 
Tarelton, 2014). Priming of the immune system with PFR protein either purified or 
recombinant allows for the development of a pool of PFR specific CD4 and CD8 T cells 
that can swiftly recognize T. cruzi infected cells shortly after infection. Thus, allowing for 
the immunity seen in immunization studies. 
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CRISPR/Cas9 Discovery 
The first description of clustered regularly interspaced short palindromic repeats 
(CRISPR) was by Ishino et al in 1987. At the time Ishino was working on a project where 
he was sequencing a 1.7Kb region of the Escherichia coli genome that contained the 
isozyme of alkaline phosphatase (iap) gene (Ishino et al., 1987). It was while analyzing 
the sequence downstream of the iap gene that Ishino et al. (1987) found five homologous 
sequences (29nt long) that were spaced 32nt apart. In addition to this unusual clustering, 
the group found that the center of the homologous regions contained palindromic 
sequences (Ishino et al., 1987). At the time the research group did not understand the 
function of these repeated sequences but did acknowledge the unique finding in their 
publication on iap. Soon after this discovery, other research groups found similar repeats 
in Shigella spp. and Mycobacterium tuberculosis, indicating that E. coli was not unique 
(Nakata et al., 1989). 
Several years after the initial discovery in E. coli, similar repeats were found 
within the archaea Haloferax mediterranei (1993) and H. volcanii (1995) (Mojica et al.). 
This discovery was unique, as these repeats had previously only been found in bacteria. 
In an attempt to elucidate the role of these repeats in Haloferax spp. the researchers 
behind these discoveries, Mojica et al. (1995), transformed the archaea with recombinant 
plasmids containing these repeats. What they found was that the addition of extra repeats 
decreased cell viability as well as lead to differing DNA distribution among dividing cells 
(Mojica et. al; 1995). Due to these results, the researchers proposed that the repeats 
function in the partitioning of replicated DNA into daughter cells (Mojica et. al; 1995). 
Mojica went on to test this partitioning hypothesis in E. coli but did not find the same 
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results, suggesting a different function for these repeats (Monjica et al., 2016). 
The late 90s saw a revolution in DNA sequencing, with new techniques allowing 
for the publication of the first complete genome sequence of a free-living organism 
(Haemophilus influenzae) (Fleischmann et al., 1995). Following this publication, the 
number of complete genomic sequences for bacteria and archaea increased, with a total of 
26 publicly available by the end of the 90s (Monjica et al., 2016). While sequencing these 
genomes, researchers began to find repeats similar to those found by Ishino and Mojica, 
but since there were no programs available to accurately identify these repeats, they could 
often be difficult to find. In a study done by Mojica et al. (2000), they were able to utilize 
a computer program to search complete and partial genomes for these repeats, at the time 
called Short Regularly Spaced Repeats (SRSRs). The results of these searches showed 
that SRSRs were only present in bacteria and archaea and were not confined to particular 
phylogenic groups. In addition, Mojica et al (2000). provided a concise description of the 
main features of SRSRs: (1) short sequences (24-40bp) with an up to 11bp long 
palindromic region (2) repeated sequences are arranged in clusters, with up to 14 clusters 
in one genome (3) unique spacer sequences (20-58bp) separate the repeats within a 
cluster (Mojica et al., 200). This set of features indicated that SRSRs serve a common 
function among the bacteria and archaea that have them.   
The influx of complete and partial genomic sequences not only help Mojica begin 
to elucidate the true function of SRSRs but also aided in the discovery of several genes 
associated with them. In a study by Jansen et al. (2002) they used a computer program, 
similar to Mojica et al., to expand on the list of organisms with SRSRs (renamed to the 
universally accepted CRISPR). While searching for CRISPR loci the researchers also 
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looked at common genes that flanked the loci. What they found were four genes, 
designated CRISPR-associated genes (cas) 1-4, that were present in prokaryotes with loci 
and absent in those without the loci (Jansen et al., 2002). Not all CRISPR containing 
prokaryotes had all of the cas genes but they did have cas1 in conjunction with one or 
more of the three other genes (Jansen et al., 2002). The researchers were not able to 
determine how CRISPR loci and cas genes interacted but were able to predict, based on 
structure, that the proteins for cas3 and cas4 were most likely involved in DNA 
modification and DNA binding respectively (Jansen et al., 2002). 
Shortly after the discovery of the cas genes two independent labs, Mojica et al. 
(2005) and Pourcel et al. (2005), published similar findings on the spacer regions within 
the CRISPR loci. Both labs sequenced the loci of various prokaryotes and compared them 
to known sequences in the GeneBank database. What they found was that many of the 
spacer sequences were homologous to regions within bacteriophage genomes (Mojica et 
al. and Pourcel et al., 2005). To hypothesize the purpose of these homologs, both groups 
turned to previous publications that focused on whole genome sequencing. The product 
of these literature searches revealed that prokaryotes containing spacers for a particular 
bacteriophage did not contain any DNA from that phage within its genome (Mojica et al. 
and Pourcel et al., 2005). Since genome integration is vital for the bacteriophage 
lysogenic lifecycle it was concluded that the CRISPR loci could be conferring immunity 
against particular phages. In addition to these common findings, both groups provided 
separate conclusions on the mechanism behind immunity or how new spacers may be 
incorporated. Mojica et al. (2005) found during their sequencing efforts that the spacers 
often targeted genes necessary for phage survival and replication. The targeting of these 
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genes in conjunction with prior knowledge that CRISPR loci produce RNA transcripts 
lead them to the conclusion that immunity could function similar to eukaryotic RNAi 
(Mojica et al., 2005). Pourcel et al. (2005) found when comparing the order of spacers 
between the loci of their related prokaryotes that newer spacers were added to the front of 
the loci. This led them to suggest that insertion of new spacers is most likely done by 
simultaneously duplicating the homologous region at the beginning of the loci and 
inserting the spacer.  
Building on the idea that CRISPR functioned similar to RNAi Makarova et al. 
(2006) preformed an analysis of Cas protein sequences to determine their functions and 
find functional analogies to proteins within the RNAi system. What they found were 
analogous proteins for dicer, slicer, and RNA-dependent RNA polymerase (Makarova et 
al., 2006). In addition, they proposed that the spacer regions performed similar functions 
to siRNAs by binding to specific sequences, such as invading DNA and targeting them 
for degradation (Makarova et al., 2006). Within their conclusion, Makarova et al. (2006) 
pointed out that although CRISPR had many analogies to RNAi this system also 
resembled adaptive immunity within vertebrates, due to its memory component. 
CRISPR’s role in bacterial adaptive immunity was experimentally shown in 2007 by (1) 
infecting Streptococcus thermophilus with bacteriophage and examining their CRISPR 
loci (2) removing spacers from S. thermophilus and testing their susceptibility to phage 
infection (Barrangou et al.). The results of the first set of experiments showed that post 
infection, those bacteria that developed resistance had acquired new spacer sequences at 
the proximal end of the CRISPR locus (Barrangou et al., 2007). In addition, factors such 
as which spacers were acquired, number of spacers acquired, and the presence/absence of 
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single nucleotide polymorphisms affected phage immunity (Barrangou et al., 2007). The 
results of the second set of experiments revealed that removal of particular spacers 
decreased immunity to particular phages (Barrangou et al., 2007). Since the publishing of 
the study, much of the process by which the various components of CRISPR function to 
produce adaptive immunity has been pieced together.   
Adaptive Immunity in Prokaryotes 
Adaptive immunity in prokaryotes follows three main steps: (1) adaptation – 
acquisition of new spacer sequences from invading bacteriophage, (2) crRNA biogenesis 
– transcription and processing of the CRISPR array, and (3) targeting – crRNA guided 
Cas endonucleases cleaves invading DNA (Barrangou and Marraffini, 2014). The 
proteins and protein complexes utilized in each step can varying among prokaryotes with 
the CRISPR-Cas system diverging into six main types. These six types (I, II, III, IV, V, 
VI) differ mainly in the type of endonuclease used to cleave foreign DNA, with type I 
using Cas3, type II Cas9, type III Cas10, type IV Csf1, type V Cpf1, and type VI Cas13 
(Makarova et al., 2015). Type II (Cas9) is the most commonly used type in gene editing 
research due to its use of only a single multidomain nuclease to induce double stranded 
breaks within the DNA. 
Using the type II system as an example for adaptive immunity in prokaryotes, the 
process of adaptation starts with the transcription of cas1 and cas2 (proteins part of the 
cas operon). Cas1 and Cas2 form a complex responsible for cleaving portions (25-65nt) 
of invading DNA and inserting them at the proximal end of the CRISPR array (region of 
the CRIPSR locus that contains all of the spacers and repeats; serves as the memory bank 
for the immune system) (Mir et al., 2018). In some cases, csn2 is present in the cas 
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operon and is transcribed along with cas1 and cas2 (Mir et al., 2018). The exact function 
of Csn2 in spacer acquisition is not fully understood but it has been noted that it is able to 
bind to the Cas1/Cas2 complex (Ka et al., 2018). This ability to bind has hinted at the 
possibly of Csn2 serving as a scaffold that helps to anchor the proteins of the Cas1/Cas2 
complex together (Ka et al., 2018). 
 Following reinfection with a bacteriophage that has been logged into the CRISPR 
array, crRNA biogenesis occurs. In this biogenesis, the CRISPR array, cas9, and 
tracrRNA (sequence that contains a homologous region to the repeats within the array) 
are all transcribed (figure 3). The CRISPR array is often transcribed as a single transcript 
called pre-crRNA that is then further processed to produce individual crRNA (Hille and 
Charpentier, 2016). There are some instances where there are promoters within the 
repeated sequences, allowing for varying length of pre-crRNA (Hille and Charpentier, 
2016). Following transcription of the array, tracrRNA binds to its complementary 
sequence in the repeat creating an RNA duplex that can be bound by Cas9 (figure 3) 
(Hille and Charpentier, 2016). Following the formation of the duplex, RNase III separates 
the individual pre-crRNA:tracrRNA complexes from one another, producing mature 
crRNA (figure 3) (Hille and Charpentier, 2016).  
The mature crRNA is used in the targeting step, to guide Cas9 endonucleases to 
invading DNA. This guiding is accomplished by the spacer region in the mature crRNA 
binding to its complementary sequence with the bacteriophage DNA. Once bound to this 
sequence Cas9 will cleave the DNA, rendering it incapable of continuing infection; 
crRNA’s often target regions important for phage survival, such as DNA replication and 
phage integration (Mojica et al., 2005). Within the Cas9 endonuclease, there are two 
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domains (HNH and RuvC) which administer cuts to the invading DNA (Doudna and 
Charpentier, 2014). HNH induces a break within the strand complementary to the 
crRNA, while RuvC induces a break in the other strand (Doudna and Charpentier, 2014). 
The presence of both domains within one nuclease is what has made the Cas9 system the 
preferred system for gene editing.  
The binding crRNA to its complementary sequence is not the only thing required 
for Cas9 to cut. Small sequences known as protospacer adjacent motifs (PAM) must be 
present either directly upstream or downstream of the target site. The purpose of the 
PAM sequence is to make the CRISPR/Cas system specific for foreign DNA and prevent 
self-targeting (Hille and Charpentier, 2016). Due to this PAM requirement, Cas9 is 
sometimes used to select spacers before Cas1, Cas2, and Csn2 incorporate them into the 
CRISPR array (Mir et al., 2018). Following the recognition of a PAM site by Cas9’s 
PAM interacting domain (PID), Cas9 will induce its double stranded break 3nt upstream 
of the PAM sequence, effectively inhibiting infection (Mir et al., 2018).  
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Using CRISPR/Cas9 for Gene Editing in the Lab 
 CRISPR/Cas9 within a laboratory setting has been modified from its prokaryotic 
origins to utilize, in its most basic format, a Cas9 endonuclease and a single guide RNA 
(sgRNA). The sgRNA combines a unique spacer region, selected by the researcher, and 
tracrRNA that can be expressed within a single transcript. These two components can 
take on a variety of forms when being transfected or injected into organism, such as: 2 
separate plasmids (one for sgRNA and one for Cas9), a single plasmid (with both sgRNA 
and Cas9), rna transcripts of both components, or a rna transcript of the sgRNA and 
protein complex of Cas9 (Thurtle-Schmidt and Lo, 2018). Regardless of the format used 
Figure 3 Illustration detailing (1) the arrangement of the CRISPR locus and the 
transcription/translation of the components required for immunity (2) formation of 
individual crRNA:tracrRNA/Cas9 complexes from a single pre-crRNA transcript (3) 
final structure of the complex used to induce double stranded breaks within phage DNA 
(Modified from Hegasy). 
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the end result is a Cas9/sgRNA complex that is able to deliver a double stranded break at 
a specific location within the genome.   
 Using the single plasmid method as an example, as it is one of the more common 
methods used, CRISPR/Cas9 gene editing starts with selecting a region within a genome 
to edit and selecting a spacer sequence. The spacer sequence is around 20nt long and 
contains the point at which the gene editing event, a double stranded break, will occur. 
When selecting a spacer sequence, the location of PAM sequences (5’- NGG -3’ for 
Streptococcus pyogenes, the most commonly used endonuclease) has to be taken into 
consideration since Cas9 cannot function without its presence (Addgene, 2017). The 
requirement of this PAM sequence is one of the limitations of this technology, as if one is 
not available near the desired target region then another method of gene editing may have 
to be used. Another point that must be taken into consideration when selecting a spacer 
sequence is the likelihood of off target cuts with a particular sequence. The likelihood of 
this kind of event depends on the degree of similarity between a chosen spacer sequence 
and other sequences within a genome. To minimize the chance of choosing a sequence 
with high likelihood, many researchers utilize computer programs whose sole purpose is 
to provide spacer sequence options.   
Following selection of the sequence, the spacer must be incorporated into the 
sgRNA structure. This can be accomplished by designing DNA oligos that contain the 
spacer sequence and using them to amplify a plasmid that contains the sequence for the 
tracrRNA, resulting in copies of a single sequence that contains both the spacer and the 
tracrRNA sequence. Once amplified, the sgRNA can be cloned into a plasmid that 
contains the sequence for the Cas9 endonuclease. This single plasmid contains both 
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sgRNA and Cas9, which can then be transfected or injected into the desired organism. 
Within the organism, the contents of the plasmid will be expressed and processed, 
producing Cas9 endonucleases that are guided by sgRNA. These guided Cas9’s will 
induce double stranded breaks 3nt upstream of the PAM sequence (Mir et al., 2018). This 
double stranded break can be repaired by either non-homologous end joining (NHEJ) or 
homology directed repair (HDR). Non-homologous end joining is the more common 
mechanism for repair as it does not require template DNA for repair, rather it relies on 
ligation of the two ends of the break. Due to the lack of a template this mechanism can 
lead to insertions or deletions of nucleotides, resulting in mutations (Addgene, 2017). The 
potential for mutations allows this mechanism of repair to be exploited for CRISPR/Cas9 
gene knockouts. Homology directed repair, the less efficient of the two repair 
mechanism, utilizes template DNA that is homologous in sequence to the region that 
requires repair. In the case of gene editing via CRISPR/Cas9 the template DNA comes in 
the form of donor DNA that is transfected/injected along with the sgRNA/Cas plasmid. 
The donor DNA contains a desired insert, which is flanked by two regions of homology 
(homologous arms) that correspond to either side of the break. The use of donor DNA 
allows researchers to insert various sequences, such as mutations, gene tags, or antibiotic 
resistance genes into specific regions within the genome.   
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CHAPTER III 
MATERIALS AND METHODS 
Trypanosoma cruzi Culture 
CL Brenner strain epimastigotes were cultured in Schneider’s complete media 
supplemented with 20% heat-inactivated fetal calf serum (FCS) (Gemini, Lot# 
A77F00H). Transformants were maintained in medium containing 100 µg/ml G418 and 5 
µg/ml puromycin (sigma-aldrich, cat# P8833-10MG).  
Construct Preparation 
sgRNA Amplification 
C-terminal tagging was performed according to Lander et al. (2016), utilizing 
both a sgRNA/Cas9 vector and a linear donor DNA cassette to facilitate homologous 
recombination. Protospacer sequences targeting the 3’ end of pfr2 and pfr5 were designed 
using the Eukaryotic Pathogen CRISPR guide RNA Design Tool (EuPatGDT). PCR 
amplifications of sgRNA were performed using 40ng pUC_sgRNA plasmid gifted by 
Roberto Docampo (Addgene #68710) (Lander et al., 2015) (figure 4A), 0.4μM 
protospacer specific forward primer (Table 1, primers 1-2), 0.4μM sgRNA backbone 
reverse primer (Table 1, primer 3), 25μl Q5 high-fidelity 2x master mix (NEB, cat# 
M0492S), and nanopure H2O (table 2) in a 50μl reaction. PCR conditions were: initial 
denaturation at 98°C for 2 min followed by 34 cycles of 98°C for 10s, 55°C for 20s, and 
72°C for 20s, followed by a final extension at 72°C for 2 min. PCR product was isolated 
using the Zymo gel DNA recovery kit (Genesee scientific, cat# 11-300).  
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sgRNA Subcloning 
sgRNA PCR product was subcloned into the Cas9/pTREX-n plasmid gifted by 
Roberto Docampo (Addgene #68708) (Lander et al., 2015) (figure 4B) using BamHI 
restriction sites and T4 DNA ligase (NEB, cat# M0202S). Digest conditions for both 
sgRNA and Cas9/pTREX-n plasmid were: 1μg sgRNA or plasmid, 1μl BamHI-HF 
(NEB, cat #R3136S), 5μl 10x cutsmart buffer (NEB, cat# B7204S), and nanopure H2O, 
followed by a 1hr incubation at 37°C. Immediately following digestion, plasmid DNA 
was dephosphorylated by adding 1μl of calf intestinal alkaline phosphatase (CIAP) 
(Promega, cat# M1821) to the digested plasmid and incubating at 37°C for 30min. 
Digested sgRNA and plasmid were isolated using the Zymo gel DNA recovery kit. 
Ligation conditions for sgRNA and plasmid were: 50ng of digested plasmid, 37.5ng of 
digested sgRNA, 1μl T4 DNA ligase, 2μl T4 DNA ligase reaction buffer (NEB, cat# 
B0202S), and nanopure H2O, followed by an overnight incubation in the refrigerator and 
ligase inactivation at 64°C for 10min.  
Transformation 
The ligation mixture was used to transform HB101 Escherichia coli as follows; 
3ml of Luria-Bertani (LB) broth was inoculated with a single HB101 colony. This 
inoculated broth was then incubated overnight in a shaking incubator set at 37°C and 
250rpm. 500μl of the overnight culture was then used to inoculate 50ml of LB broth. The 
newly inoculated broth was incubated for 3 hours in a shaking incubator set at 37°C and 
150rpm, before incubating on ice for 30min. After incubation on ice, the entire volume of 
the culture was transferred to a 50ml conical tube and centrifuged at 6000rpm for 5min at 
4°C. The supernatant was then poured off and the cell pellet was resuspended in 5ml of 
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50mM CaCl2 and left to incubate for 20min on ice. Following incubation, the cells were 
centrifuged at 6000 rpm for 5min at 4°C. The supernatant was again poured off and the 
cell pellet was resuspended in 2.5ml of 50mM CaCl2 with 10% glycerol. The cell 
suspension was then aliquoted into 0.7ml microcentrifuge tubes, 100μl per tube, and snap 
frozen using liquid nitrogen. When it came time to perform the transformation the desired 
number of aliquots were thawed on ice. After thawing 2μl of ligation mixture was added 
to the aliquots and they were incubated on ice for 30 min. The aliquots were then heat 
shocked cells at 42°C for 1 min before returning to ice. The heat shocked cells were then 
transferred to glass culture tubes with 1ml of LB broth and incubated for 2 hours in a 
shaking incubator set at 37°C and 250rpm. 1ml of the cultures was transferred and spread 
onto LB/ampicillin agar plates, which were incubated overnight at 37°C.  
Colonies were checked for presence of sgRNA/Cas9/pTREX-n plasmid, with 
sgRNA in correct orientation, using PCR of plasmid isolated with the Zyppy plasmid 
miniprep kit (Genesee Scientific, cat# 11-308). 25µl reactions were performed using 
20ng of plasmid DNA, 12.5ul Apex Taq RED Master Mix (Genesee Scientific; cat# 42-
138), 0.4µM protospacer specific forward primer (Table 1, primers 1-2), 0.4µM of a 
reverse primer that binds to the HX1 trans-splicing site (Table, 1 primer 4), and nanopure 
H2O. PCR conditions were: initial denaturation at 95°C for 3 min followed by 34 cycles 
of 95°C for 30s, 60°C for 20s, 72°C for 20s, followed by a final extension at 72°C for 5 
min. Plasmid from positive PCR’s were sequenced to confirm correction orientation and 
sequence of sgRNA. Prior to transformation multiple minipreps were performed and the 
plasmid DNA was pooled, and ethanol precipitated. 
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Donor DNA Amplification 
Homologous arms for the Donor DNA cassettes were generated using 30nt (pfr5) 
or 100nt (pfr2) regions upstream and downstream of the estimated cut sight (3nt upstream 
of the protospacer adjacent motif). Amplification of donor DNA cassettes was done using 
50µl PCR reactions containing 40ng pMOTag2H plasmid gifted by George Cross 
(Addgene #26296) (figure 4C), 2µl DMSO, 25µl Q5 high-fidelity 2x master mix, 0.4µM 
forward and reverse primers containing homologous arms (Table 1, primer 5-8), and 
nanopure H2O. PCR conditions were: initial denaturation at 98°C for 2/3 min (pfr2/pfr5) 
followed by 40/34 cycles (pfr2/pfr5) of 98°C for 20sec, 63/72°C (pfr2/pfr5) for 20s, and 
72°C for 1min 40s/1 min (pfr2/pfr5), followed by a final extension at 72°C for 10/2 min 
(pfr2/pfr5). PCR product was purified using the DNA clean and concentrator kit 
(Genesee Scientific, cat#11-302C). Prior to transformation multiple PCRs were 
performed and the donor DNA was pooled, and ethanol precipitated.   
 
# Primer name 5’-3’ Primer sequence 
1 PFR2-sgrna GATCGGATCCTGGGTGGCACCGGCGGACACGTTTTAG
AGCTAGAAATAGC 
2 PFR5-sgrna GATCGGATCCGACTAAAGAGCCTCCTCGTGGTTTTAG
AGCTAGAAATAGC 
3 sgRNA-rv CAGTGGATCCAAAAAAGCACCGACTCGGTG 
4 HX1-rv TAATTTCGCTTTCGTGCGTG 
5 PFR2-HR1 GGAGGAGGTGAAGATTGCGGCGGAGCGCGAGGAACTG
AAGCGCTCCAAGACACTGCAGAGCCAGCAGTACCGCG
GCAAGACGGTGCAGCAGATCACACAGGGTACCGGGCC
CCCCCTCGAG 
Table 1 Primers used in construct preparation and gene tagging confirmation. 
Underlined text for sgRNA primers indicates gene specific protospacer, while for donor 
DNA it indicates homologous arms. Bolded text indicates BamHI restriction sites. 
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6 PFR2-HR2 CGGCAGTGGACTTGGTTTCCTATTTTTTCCTACAATGGA
GATATTACATAAAAAACATACATGGAATGGGGAAAAC
AGCAACAGCGTTGGGTGGCACCGGTGGCGGCCGCTCT
AGAACTAGTGGAT 
7 PFR5-HR1 ACAGGGCTATTTCCCATCAACTACGTTGTGGGTACCGG
GCCCCCCCTCGAG 
8 PFR5-HR2 AAAAAAAAAAAAAGAGTTTGTCTCACACACTGGCGGC
CGCTCTAGAACTAGTGGAT 
9 Puro-rv TCAGGCACCGGGCTTGCGGG 
10 PFR2-fv GGCATTGAGTTTGTGCATCCC 
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Figure 4 Maps of the plasmids used in the (A) amplification of sgRNA, (B) creation of sgRNA/Cas9 plasmid, and (C) the 
amplification of donor DNA. (A) The pUC_sgRNA plasmid contains the sequence for tracrRNA and an ampicillin 
resistance gene. (B) The Cas9/pTREX-n plasmid contains a ribosome promoter, HX1 trans-splicing site, GFP fused Cas9, 
and neomycin and ampicillin resistance genes. (C) The pMOTag2H plasmid contains a 3xhemaglutinin (HA) tag, tubulin 
intergenic region, and puromycin and ampicillin resistance genes. Maps made using benchling.com.    
A 
B 
C 
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Cell Transfection 
T. cruzi epimastigotes were cultured in Schneider’s complete media supplemented 
with 20% FCS until reaching a density of 1-2x107cells/ml. Once reaching this density 
cells were transferred to a 15ml conical tube and centrifuged at 1,200rpm for 10 min. The 
supernatant was then poured off and the cells were washed with 5ml of phosphate 
buffered saline (PBS) by resuspending the cell pellet in the PBS and then centrifuging at 
1,200rpm for 10min. The supernatant was again poured off and the cell pellet was 
resuspended in cold Tb-BSF (5mM KCl, 0.15mM CaCl2, 90mM Na2HPO4, 50mM 
HEPES, pH 7.3) at a concentration of 1x108cells/ml. Following the layout presented in 
table 2, 400μl of epimastigotes, 10-25µg plasmid construct, and 10-25µg donor DNA was 
added to pre-chilled 2mm electroporation cuvettes (BTX, cat#45-0125). Before 
electroporation cuvettes were placed on ice for 10min. The BTX ECM 830 
electroporation system was used to deliver 3 pulses (~1.3kV 100µs) to all cuvettes, with 
cuvettes being placed on ice for 1 min between each pulse. Following electroporation, 
epimastiogtes were allowed to recover at room temperature for 15 min before being 
transferred to suspension culture flasks (Genesee scientific, cat# 25-213) containing 5ml 
of Schneider’s complete media supplemented with 20% FCS. 24 hours after 
electroporation antibiotics (100 µg/ml G418 and 5 µg/ml puromycin) were added to the 
medium. The medium was changed each week by transferring the contents of the flasks 
to 15ml conical tubes, centrifuging at 800-1,200rpm for 10 min, pouring off the 
supernatant, and resuspending the cell pellet in 5ml of media with antibiotics. After 5 
weeks under antibiotic selection epimasitogtes transfected with pfr2 specific plasmid and 
donor, DNA were diluted into 96 well plates (figure 5).   
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Control Pfr2 
transfection 
Pfr2 
transfection 
Pfr5 
transfection 
Pfr5 
transfection 
Pfr5 
sgRNA/Cas9 
plasmid 
control 
400μl 
1x108cells/ml 
epimastigotes 
31μl donor 
dna (24.7μg) 
25μl donor 
dna (19.9μg) 
35μl donor 
dna (24.7μg) 
16μl donor 
dna (11.2μg) 
4.8μl plasmid 
dna (3.8μg) 
 28μl plasmid 
dna (24.9μg) 
24μl plasmid 
dna (24.5μg) 
31μl plasmid 
dna (24.7μg) 
16μl plasmid 
dna (12.7μg) 
80μl 
1x108cells/ml 
epimastigotes 
 400μl 
1x108cells/ml 
epimastigotes 
400μl 
1x108cells/ml 
epimastigotes 
400μl 
1x108cells/ml 
epimastigotes 
400μl 
1x108cells/ml 
epimastigotes 
 
 
 
 
 
 
Table 2 Set up of the six cuvettes used during a single round of transfection.  
Figure 5 Layout of the limiting dilution performed with epimastigotes transfected 
with pfr2 specific constructs. Bolded well (A1) represent initial inoculum that was 
diluted 2-fold down the first column (green arrow) and then diluted 2-fold across (blue 
arrows) the 96 well plate.   
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PCR Confirmation 
Pfr2 sgRNA/Cas9/pTREX-n plasmid and donor DNA integration was assessed 
using PCR of genomic DNA from suspected double resistant mutants. Genomic DNA 
was obtained by centrifuging parasites at 1,200rpm for 10 min followed by resuspension 
in 50µl of nanopure H2O and incubation at 60°C for 10 min. 25µl PCR reactions were 
performed using 5µl genomic DNA, 12.5µl Apex Taq RED Master Mix, 6.5µl nanopure 
H2O, and 0.4µm forward and reverse primer (Table 1, Primers 1 and 4 for plasmid 
identification; primers 9 and 10 for donor DNA identification). PCR conditions for 
plasmid confirmation were: initial denaturation at 95°C for 3min, followed by 34 cycles 
of 95°C for 30s, 60°C for 20s, 72°C for 20s, followed by a final extension at 72°C for 
5min. PCR conditions for gene tagging confirmation were: initial denaturation at 95°C 
for 3min, followed by 34 cycles of 95°C for 30s, 55°C for 30s, 72°C for 1min 40s, 
followed by a final extension at 72°c for 10min.      
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CHAPTER IV 
RESULTS 
Selection of sgRNA Sequences 
Construction of gene specific sgRNA/Cas9/pTREX-n plasmids started with the 
selection of 20nt long guide sequences between 20nt upstream and 50nt downstream of 
the stop codon. Guide sequence selection was done using EuPaGDT, which is an online 
program that designs guide sequences by searching uploaded genomes for 20nt sequences 
next to protospacer adjacent motifs (PAM) (5’-NGG-3’) (figure 6). In addition to finding 
guide sequences, EuPaGDT provides the number of off target hits for each designed 
guide sequence (figure 6). Following selection, guide sequences were incorporated into 
forward primers that contained a BamHI restriction site at the 5’ end (Table 1, primers 1 
and 2).  
 
A 
B 
Figure 6 EuPaGDT results for selected guide sequences (A) pfr2 and (B) pfr5. 
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sgRNA Amplification 
The forward primers, containing the guide sequences, were used in conjunction 
with a reverse primer that also contained a BamHI restriction site, to amplify 
pUC_sgRNA plasmid that contained the sequence for tracrRNA (Table 1, primers 1, 2, 
and 3). Finding the correct PCR conditions for maximum amplification took several 
iterations before arriving at the reaction mixture and thermocycler program presented in 
the methods section. The first iteration included a 50μl PCR reaction with 40ng 
pUC_sgRNA, 25μl Q5 high-fidelity 2x master mix, nanopure H2O, and 0.5μM sgRNA 
forward and reverse primers (Table 1, primers 1 and 3). The PCR conditions were: initial 
denaturation at 94°C for 2 min, followed by 34 cycles of 94°C for 15s, 52°C for 20s, and 
72°C for 20s, followed by a final extension at 72°C for 20s. This set up was only used for 
pfr2 sgRNA amplification and resulted in a faint band that appeared to be at the correct 
size (122bp) (figure 7A). For the next iteration, we increased the denature temperature, 
from 94°C to 98°C to align with the PCR protocol provided by the supplier of the 
polymerase. In addition, we decreased the concentration of primer used to one consistent 
with the standard PCR reaction set up utilized in our lab. This 25μl PCR reaction 
consisted of 40ng pUC_sgRNA plasmid, 12.5μl Q5 high-fidelity 2x master mix, 
nanopure H2O, and 0.4μM sgRNA forward and reverse primer (Table 1, primers 1 and 3). 
The PCR conditions were: initial denaturation at 98°C for 3min, followed by 34 cycles of 
98°C for 10s, 52°C for 20s, and 72°C for 20s, followed by a final extension at 72°C for 2 
min. This set up was also only used for pfr2 sgRNA amplification and resulted in a faint 
band that appeared to be at the right size (122bp) (figure 7B). For the final iteration, 
which is described in the methods, we increased the annealing temperature from 52°C to 
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55°C, which was a temperature calculated by the Tm calculator available by the supplier 
of the polymerase. This set up resulted in the brightest bands, at 122bp, and was used for 
the amplification of all the pfr2 and pfr5 sgRNA that was used in subsequent cloning 
(figure 7C). Prior to cloning all sgRNA PCR product was run on an agarose gel to 
confirm size; bands were excised from the gel and DNA was recovered using the Zymo 
gel DNA recovery kit. 
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bp sgRNA A 
1,517 
1,200 
900 
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600 
800 
bp sgRNA B 
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2,000 
1,500 
1,000 
700 
500 
300 
100 
bp sgRNA 
C 
Figure 7 Agarose gel electrophoresis images showing the results of the three different 
PCR reaction set ups tested for sgRNA amplification. (A and B) Results of the first 
two PCR set ups tested. These set ups were only used for pfr2 sgRNA amplification 
and both resulted in the faint bands present within the red boxes. (C) Result of the 
final PCR set up tested. This agarose gel image is representative of what both pfr2 and 
pfr5 sgRNA amplification looked like. Expected size for all sgRNA amplification was 
122bp.   
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Subcloning sgRNA into Cas9/pTREX-n 
 Amplified and recovered sgRNA, for both pfr2 and pfr5, was subcloned into 
Cas9/pTREX-n plasmid, between the ribosome promoter and HX1 trans-splicing site, 
using BamHI restriction sites on both the sgRNA and the plasmid. Prior to ligation, 
digestion of both was confirmed using agarose gel electrophoresis with product at the 
correct size (122bp sgRNA, 11.2kB Cas9/pTREX-n) being excised and recovered with 
the Zymo gel DNA recovery kit (figure 8). Following ligation, E. coli was transformed 
with the ligation mixtures. Several transformation protocols were tested before reaching 
the final version presented in the methods. The first protocol used was a CaCl2 
transformation using JM109 E. coli (Table 3, column 1). This method was used only with 
pfr2sgRNA/Cas9/pTREX-n ligation solution and resulted in no colony growth. For the 
next transformation the CaCl2 protocol was modified by decreasing the amount of 
ligation solution added (5μl to 2μl), decreasing the length of the heat shock (2 min to 
45s), and increasing the volume of cell transferred to the LB/AMP plates (100μl to 1ml) 
(Table 3, column 2). The reasons for these changes were to decrease the potential for the 
components of the T4 ligation reaction buffer to hinder transformation, decrease the 
potential for cell death during heat shock, and increase the likelihood of having at least 
one colony grow on the plates. This modified protocol resulted in the growth of several 
colonies, although the colonies were smaller than expected.  At the same time, we 
performed this modified protocol, we also tried an electroporation protocol using JM109 
E. coli (Table 4, column 1). This protocol also resulted in growth of several small 
colonies. In order to determine if these colonies contained pfr2sgRNA/Cas9/pTREX-n 
plasmid with the sgRNA in the correct orientation, we performed colony PCR on several 
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of the colonies from the CaCl2 protocol and the electroporation protocol. The 25μl PCR 
reactions performed contained 12.5μl Q5 high-fidelity 2x master mix, nanopure H2O, 5μl 
template DNA (one bacterial colony added to 5μl nanopure H2O), and 0.8μM forward 
and reverse primer (Table 1, primers 1 and 4). The PCR conditions were: initial 
denaturation at 98°C for 2 min followed by 34 cycles of 98°C for 20s, 60°C for 20s, and 
72°C for 20s, followed by a final extension of 72°C for 5 min. The results of the colony 
PCR showed the presence of bands below the expected size of 190bp, indicating the 
absence of the correct plasmid (figure 9A). For the next transformation we modified the 
electroporation protocol by using HB101 E. coli instead of JM109, changing the 
percentage of glycerol used (50% to 10%), increasing the amount of ligation solution 
used (1μl to 2μl), trying an additional electroporator setting (1,800v and 5ms), culturing 
the cells post electroporation, and transferring a larger volume of cell suspension to the 
LB/AMP plates (40μl to 100μl) (Table 4, column 2). The changes in glycerol percentage 
and electroporator settings were inspired by an undergraduate researcher (Noah Gorski) 
who was working on a protocol for bacterial electroporation. The change in E. coli strain 
was done to see if one strain was better at taking up the plasmid than the other, while the 
rest of the changes were done to increase likelihood of getting transformants on the 
plates. This protocol did not result in the growth of colonies. The next transformation was 
a modification of the previous modification, for the electroporation protocol. This 
modification increased the volume of ligation solution used (2μl to 5μl) replaced the 
1,800v/5ms electroporator setting with the 2,500v/90μs setting and increased the culture 
time post electroporation (30 min to 1 hour). The protocol resulted in the growth of 
several colonies that also had satellite colonies. Due to the presence of these few colonies 
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this protocol was also used for the first time with pfr5sgRNA/Cas9/pTREX-n ligation 
mixture, which did not result in colony growth. The colonies from the pfr2 
electroporation were test for the presence of the plasmid using PCR of plasmid DNA 
isolated through the Zyppy plasmid miniprep kit. The 25μl PCR reaction included 1μl of 
plasmid DNA, 12.5μl of Apex Taq Red master mix, nanopure H2O, and 0.4μM forward 
and reverse primer (Table 1, primers 1 and 4). The PCR conditions were initial 
denaturation at 95°C for 3 min, followed by 34 cycles of 95°C for 30s, 60°C for 20s, and 
72°C for 20s, followed by a final extension at 72°C for 5 min. The results of this PCR 
showed the presence of several bands above the desired 190bp, indicating these bacteria 
did not contain the correct plasmid (figure 9B). The next transformation protocol tested 
was another CaCl2 protocol, but with HB101 (Table 3, column 3). This protocol was used 
for both pfr2sgRNA/Cas9/pTREX-n and pfr5sgRNA/Cas9/pTREX-n ligation mixtures 
and resulted in the growth of a single colony on the pfr5 transformed plate. This colony 
was tested for the presence of the plasmid in the same way the prior 
pfr2sgRNA/Cas9/pTREX-n electroporation colonies were tested (figure 9C). The results 
of the PCR were similar to that of the prior pfr2 PCR, indicating that this bacterial colony 
did not contain the correct plasmid. The final transformation protocol tested was the one 
presented in the methods. This method used both the pfr2sgRNA/Cas9/pTREX-n and 
pfr5sgRNA/Cas9/pTREX-n ligation mixture and produced the most colonies and unlike 
the first couple of CaCl2 transformations tried, this protocol produced bacterial colonies 
of an average size. Following the PCR protocol outlined in the methods, the colonies 
were tested for the presence of the plasmid, with sgRNA in the correct orientation. The 
results of the PCR showed the presence of a band at the 190bp for several of the colonies 
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tested (figure 9D).  Plasmids that had a positive PCR amplification were sent to 
GenScript for Sanger sequencing. Results of the sequencing were checked against the 
expected sequence using the Clustal Omega sequence alignment tool (figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3,000 
2,000 
1,500 
1,000 
700 
500 
200 
bp sgRNA Cas9 
Figure 8 Representative agarose gel electrophoresis photo showing the digestion of 
sgRNA and Cas9 with BamHI-HF. Expected sizes: sgRNA (122bp) and Cas9 plasmid 
(11.2kB) 
49 
 
Table 3 CaCl2 protocols tested for transformation of E. coli with sgRNA/Cas9/pTREX-n ligation 
solutions. 
 
 
CaCl2 transformation protocol 
(First protocol tested for 
pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation) 
Modification to CaCl2 
transformation protocol 
(Second protocol tested for 
pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation) 
CaCl2 transformation 
protocol (Sixth protocol used 
for 
pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation and 
second protocol used for 
pfr5sgRNA/Cas9/pTREX-n 
plasmid transformation) 
1. Inoculated 3ml of LB broth 
with a single colony of JM109 
12. Added 2µl of ligation 
mixture to cell suspension and 
heat shocked at 37°C for 45s 
1. Inoculated 3 ml of LB broth 
with a single HB101 colony 
2. Incubated inoculated culture 
overnight in a shaking incubator 
set at 37°C and 250rpm  
14. Transferred and spread 
1ml of the cell solution onto 
LB/AMP agar plates 
2. Incubated inoculated broth 
overnight in shaking incubator 
set at 37°C and 250rpm  
3. Inoculated 25ml of LB broth 
with 100μl of overnight culture 
 3. Transferred 100μl of 
overnight culture to 25ml LB 
broth and incubated for 3 hours 
in a shaking incubator set at 
37°C and 150rpm 
4. Incubated culture for 3 hours in 
a shaking incubator set at 37°C 
and 150rpm 
 4. Transferred culture to pre-
chilled 50ml conical tube and 
centrifuged at 8,000 rpm for 5 
min at 4°C 
5. Incubated culture on ice for 30 
min 
 5. Poured off supernatant and 
resuspended cell pellet in 5ml 
of cold 30mM CaCl2  
6. Transferred chilled culture to a 
pre-chilled 50ml conical tube and 
centrifuged at 5,000rpm for 
10min at 4°C 
 6. Distributed the cell 
suspension among 1.5ml 
microcentrifuge tubes and 
centrifuged at 8000rpm for 30s 
7.  Poured off supernatant and 
resuspended cell pellet in 5ml of 
cold 50mM CaCl2. 
 7. Poured off the supernatant 
and resuspended in .5ml of col 
30mM CaCl2 
8. Cell suspension was incubated 
on ice for 30 min 
 8. Transferred 50μl of cell 
suspension and 2μl of ligation 
mixture to 1.5ml 
microcentrifuge tubes 
9. Cell suspension was 
centrifuged at 5,000 rpm for 
10min at 4°C 
 9. Heat shocked at 42°C for 
30s and then immediately 
place on ice for 5 min 
10. Poured of supernatant and 
resuspended the cell pellet in 1ml 
 10. Transferred contents of the 
microcentrifuge tubes to glass 
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of 50mM CaCl2 culture tubes that contained 
1ml of LB broth 
11. Transferred 200μl of cell 
suspension to a pre-chilled glass 
culture tube 
 11. Incubated culture for 1 
hour in shaker incubator set at 
37°C and 250rpm 
12. Added 5μl of ligation mixture 
to the cell suspension and heat 
shocked at 42°C for 2 min 
 12. Transferred and spread full 
volume onto LB/AMP agar 
plates  
13. Added 800μl of LB broth to 
the culture tube and incubated for 
45 min in a shaker incubator set 
at 37°C and 250rpm 
14. Transferred and spread 100μl 
of the cell solution onto LB/AMP 
agar plates 
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Table 4 Electroporation protocols tested for transformation of E. coli with sgRNA/Cas9/pTREX-n 
ligation solutions.  
 
Electroporation 
transformation protocol 
(Third protocol tested for 
pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation) 
Modifications to 
electroporation transformation 
protocol (Fourth protocol 
tested for 
pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation) 
Further modification to 
electroporation transformation 
protocol (Fifth protocol tested 
for pfr2sgRNA/Cas9/pTREX-n 
plasmid transformation and first 
protocol tested for 
pfr5sgRNA/Cas9/pTREX-n 
plasmid tranformation) 
1. Inoculated 3ml of LB broth 
with a single colony of JM109 
1. Inoculated 3ml of LB broth 
with a single colony of HB101 
 
10. Transferred 40μl of cell 
suspension and 5μl of ligation 
mixture to pre-chilled cuvettes 
2. Incubated inoculated culture 
overnight in a shaking 
incubator set at 37°C and 
250rpm 
7. Poured off supernatant and 
resuspended cell pellet in 10ml 
of 10% glycerol 
 
11. Using the BTX ECM 830 
electroporator 1 pulse set 400v and 
15s was applied to one cuvette and 
1 pulse set at 2,500v and 90μs was 
applied to another. Following 
electroporation 1ml of LB was 
added to the cuvettes and the 
contents of the cuvettes were 
transferred to glass culture tubes. 
The culture tubes were then place 
in a shaking incubator set at 37°C 
and 250rpm, for 1 hour. 
3. Inoculated 25ml of LB broth 
with 100μl of overnight culture 
10. Transferred 40μl of cell 
suspension and 2μl of ligation 
mixture to pre-chilled cuvettes 
4. Incubated culture for 3 
hours in a shaking incubator 
set at 37°C and 150rpm 
11. Using the BTX ECM 830 
electroporator 1 pulse set 400v 
and 15s was applied to one 
cuvette and 1 pulse set at 1,800v 
and 5ms was applied to another. 
Following electroporation 1ml of 
LB was added to the cuvettes 
and the contents of the cuvettes 
were transferred to glass culture 
tubes. The culture tubes were 
then place in a shaking incubator 
set at 37°C and 250rpm, for 30 
min. 
5. Incubated culture on ice for 
30 min 
12. 100μl of the cultures was 
transferred and spread onto 
LB/AMP agar plates 
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6. Transferred chilled culture 
to a pre-chilled 50ml conical 
tube and centrifuged at 
5,000rpm for 10min at 4°C 
7. Poured off supernatant and 
resuspended cell pellet in 10ml 
of 50% glycerol 
8. Centrifuged cells at 
5,000rpm for 10min at 4°C 
9. Poured off supernatant and 
resuspended cell pellet in 
remaining liquid 
10. Transferred 40μl of cell 
suspension and 1μl of ligation 
mixture to pre-chilled cuvettes 
11. Applied 1 pulse to the 
cuvette using the BTX ECM 
830 electroporator set at 400v 
and 15s 
12. The entire volume of the 
cuvettes were transferred and 
spread onto LB/AMP agar 
plates 
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Figure 9 Agarose gel electrophoresis images showing the results of the PCRs done to confirm presence 
sgRNA/Cas9/pTREX-n plasmid in the bacterial colonies from the various transformation protocols tested. (A) 
Colony PCR of the colonies produced by the modified CaCl2 and the electroporation protocol (Table 2, column 2; 
Table 3 column 1). (B) Representative image showing PCR of plasmid DNA from colonies produced by the further 
modified electroporation protocol (Table 3, column 3). (C) PCR of plasmid DNA from the colony produced by the 
2nd CaCl2 protocol (Table 2, column 3). (D) Representative image showing the PCR of plasmid DNA from colonies 
produced by the CaCl2 protocol described within the methods. Expected size was 190bp. 
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Donor DNA 
 Construction of the donor DNA cassette used for gene tagging started with 
selection of the homology arms. Cas9 endonuclease cuts 3nt upstream of the PAM site, 
so 30nt (for pfr5 gene tagging) or 100nt (for pfr2 gene tagging) long sequences on either 
side of the break were chosen as homology arms. Both lengths were chosen to test if a 
shorter length could be used for this type of gene tagging protocol and due to the high 
cost of long primers. The sequences for the homologous arms were incorporated into 
forward and reverse primers (Table 1, Primers 5-8) that were used to amplify the 
pMOTag-2H plasmid. This plasmid contained a 3x hemagglutinin (HA) tag, a tubulin 
intergenic region (tigr), and a puromycin resistance gene. Several different PCR reactions 
B 
A 
Figure 10 Clustal omega DNA sequence alignments of sgRNA/Cas9/pTREX-n 
plasmids for (A) pfr2 and (B) pfr5. Bolded sequences are BamHI restriction sites, 
underlined sequences are guide sequences, red sequences are tracrRNA, and asterix 
indicate matching nucleotides.  
Expected        AAAGCGCCGTGTGGATGCCAAGTCTGTGCAAGAGTTCTAGTGGATCCTGGGTGGCACCGG  
PFR2 Plasmid    AAAGCGCCGTGTGGATGCCAAGTCTGTGCAAGAGTTCTAGTGGATCCTGGGTGGCACCGG  
                ************************************************************ 
 
Expected        CGGACACGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTG  
PFR2 Plasmid    CGGACACGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTG  
                ************************************************************ 
 
Expected        AAAAAGTGGCACCGAGTCGGTGCTTTTTTGGATCCCCCAACGAG  
PFR2 Plasmid    AAAAAGTGGCACCGAGTCGGTGCTTTTTTGGATCCCCCAACGAG  
                ******************************************** 
 
Expected        GCCGTGTGGATGCCAAGTCTGTGCAAGAGTTCTAGTGGATCCGACTAAAGAGCCTCCTCG  
PFR5 Plasmid    GCCGTGTGGATGCCAAGTCTGTGCAAGAGTTCTAGTGGATCCGACTAAAGAGCCTCCTCG  
                ************************************************************ 
 
Expected        TGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAA  
PFR5 Plasmid    TGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAA  
                ************************************************************ 
 
Expected        GTGGCACCGAGTCGGTGCTTTTTTGGATCCCCCAACGAG  
PFR5 Plasmid    GTGGCACCGAGTCGGTGCTTTTTTGGATCCCCCAACGAG  
                ***************************************    
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mixtures and thermocycler programs were utilized throughout the creation of donor 
DNA, with all of them providing bright bands at the expected size (1.3kB – pfr2, 1.1kB – 
pfr5) (figure 11). The reason for the different PCR set ups was to increase DNA yield 
while decreasing the amount of primer used. The first PCR set up included at 50μl PCR 
reaction with 25μl Q5 high-fidelity 2x master mix, 30ng pMOTag2H, 2μl DMSO, 
nanaopure H2O, and 0.8μM forward and reverse primer (Table 1, primers 5 and 6). The 
PCR conditions were: initial denaturation at 98°C for 2min, followed by 30 cycles of 
98°C for 20s, 63°C for 20s, and 72°C for 1 min 20s, followed by a final extension at 
72°C for 10 min. This PCR set up was only used for pfr2 donor DNA amplification and 
all resulting PCR product was run on an agarose gel a recovered using the Zymo gel 
DNA recovery kit. The next PCR set up used included a 40μl PCR reaction with 25μl Q5 
high-fidelity 2x master mix, 30ng pMOTag2H plasmid, 2μl DMSO and 0.4μM forward 
and reverse primer (Table 2, primers 5-8). The set up was used for both pfr2 and pfr5 
donor DNA amplification and used the PCR conditions from the methods section. The 
main difference between this set up and the prior is the decrease in the amount of primer 
used and the use of a DNA clean and concentrator kit rather than the gel recovery kit. 
Prior to using the clean and concentrator kit a small volume (about 5μl) of PCR product 
was run on an agarose gel to confirm correct amplification. The use of the DNA clean 
and concentrator allowed for higher DNA yield from the PCR reactions. The final PCR 
set up used is the one described within the methods, with the only difference from the 
56 
 
prior set up being the increase in reaction volume from 40μl to 50μl. This increase was 
done to increase in DNA yield. 
Transfections and Antibiotic Selection 
 Four transfection and antibiotic selection protocols were tested throughout this 
study with the final protocol, which is detailed in the methods section, being the most 
successful, in terms of the length of parasite survival post transfection. The first protocol 
tested started with the growth of T. cruzi epimastigotes to a concentration of 1-2x107 
cells/ml. Once the parasite reached this concentration, they were transferred to a 15ml 
conical tube and centrifuged at 2,000 rpm for 5 min. The supernatant was then poured off 
and the cell pellet was washed by resuspending the pellet in 5ml of PBS and centrifuging 
at 2,000 rpm for 5 min. The supernatant was again poured off and the cells were 
resuspended in cold cytomix (120mM KCl, .15mM CaCl2, 25mM HEPES, 2mM EDTA, 
and 5mM MgCl2) at a concentration of 1x10
8 cells/ml. This cell suspension was then 
A B 
Figure 11 Representative agarose gel electrophoresis images of donor DNA 
amplification for gene tagging of (A) pfr2 and (B) pfr5. Expected sizes of 1.3kB (A) 
and 1.1kB (B). 
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transferred to pre-chilled cuvettes, along with pfr2 specific plasmid and donor DNA, 
according to the layout presented in table 5. Once everything had been added to the 
cuvettes, they were placed on ice to 10 min. After incubating on ice, the BTX ECM 830 
electroporator was used to deliver three electrical pulses at 1030v/90μs to each cuvette. 
Between each pulse, the cuvettes were place on ice for 1 min. Following the completion 
of the three pulses, the cuvettes were placed at room temperature for 15 min to allow the 
cells to recover. The entire volume of the cuvettes was then transferred to culture flasks 
that contained 5ml of Schneider’s complete medium with 20% FCS. 24 hours after 
transfection 250μg/ml G418 (selects for the plasmid) and 5μg/ml puromycin (selects for 
the donor DNA) was added to the flasks. The media was changed out every week by 
transferring the contents of the flask to 15ml conical tube and centrifuging them at 
700rpm for 5 min. Most of the parasites died off within the first week after transfection, 
with very few still alive in the following weeks. Many of the parasites that survived after 
the initial decline in population had decreased flagellar movement compared to wild type 
parasites.  
The next protocol tested, used the prior protocol as a foundation, with the addition 
of several modifications. These modifications included a change in centrifuge speed and 
time (2,00rpm/5min to 1,200rpm for 10min), a decrease in the volume of cells used for 
each transfection (400μl to 350μl), and a change in how the cells were cultured post 
transfection. The decrease in parasite volume was done in the hopes to decrease the 
overall volume in the cuvettes and increase the max voltage that could be applied the 
cuvettes. The voltage did slightly increase from the prior transfections done, from 
1030v/90μs to 1056v/101μs. For culturing post transfection, 24 hours after transfection 
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the contents of the culture flaks were transferred to 15ml conical tubes and centrifuged at 
1250rpm for 10 min. The supernatant was then poured off and the cells were resuspended 
in Schneider’s medium with antibiotics. This protocol of centrifuging the parasite and 
resuspending them in fresh media was repeated once a week for three weeks. After the 
three weeks, the contents of the flasks transfected with pfr2 plasmid and donor DNA 
(transfection layout in table 6) were transferred to 24 well plates, with 1 ml per well. This 
was done to allow for easier spotting of the parasites under the inverted microscope. 
Fresh media was either added directly to the well or the top half of the existing media 
was removed, and fresh media was added to replace it. Over the course of the next few 
weeks, several of the wells still had clusters of surviving parasites that and had good 
flagellar movement. These clusters would not grow frequently and would occasionally 
decrease in populations numbers. This trend continued until it was decided to move on to 
a new transfection, due to low parasite numbers.  
The next protocol tested built upon the prior protocol with a few modifications. 
These modifications included a decrease in cell concentration (1x108 to 2.27x107 
cells/ml), a decrease in G418 added post transfection (250 to 100μg/ml), and a change in 
cell culturing post transfection. The change in cell concentration was due to the 1x108 
cells/ml concentration not producing the volume necessary to perform all of the 
transfections required (layout in table 7), while the change in G418 concentration was 
done to see if cell viability would increase. For culturing post-transfection, 24 hours after 
transfection the contents of the culture flasks were transferred to 15 ml conical tubes, 
diluted (1:2 and 1:4), and transferred to 96 well plates (200μl per well) (figure 12). Half 
of the media was removed each week and replaced with fresh media with antibiotics. 
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Within a few weeks after transfection, most of the parasites transfected with pfr5 plasmid 
and donor DNA had died and no parasite clusters (sign of population growth) could be 
seen.      
The final protocol performed was the one detailed in the methods section. Similar 
to the other protocol this one built off the prior with modifications. The main 
modifications implemented during this protocol included an increase in voltage 
(1056v/101μs to 1340v/100μs), change in electroporation buffer used (cytomix to Tb-
BSF), and a change in culturing techniques post transfection (figure 5). The increase in 
voltage was accomplished through decreasing the volume of plasmid and donor DNA 
that needed to be added to the cuvettes, which allowed for a decrease in the total volume 
within the cuvettes (table 2). This decrease in plasmid and donor DNA volume was 
accomplished through increased efficiency during miniprep and ethanol precipitation 
procedures. The change in electroporation buffers was done to help decrease cell death 
immediately following transfection. This decrease in cell death was seen during this 
round of transfections, with both the control cells and the plasmid and donor DNA 
transfected cells having either minimal cell death or less cell death compared to cytomix, 
24 hours post transfection. This protocol was our most successful in terms of cell 
viability post transfection with parasites showing signs of cell growth six plus weeks after 
transfection. These signs of cell growth were only seen with the parasites transfected with 
pfr2 plasmid and donor DNA, while those transfected with pfr5 plasmid and donor DNA 
saw continuously dwindling populations over the course of several weeks. Although the 
pfr2 transfected parasites did show positive signs of growth they never reached numbers 
comparable to those seen when culturing wild type T. cruzi.      
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Pfr2 transfection Pfr2 transfection  Control Control  
40μl pfr2 
sgRNA/Cas9/pTREX-
n plasmid (28μg) 
26μl pfr2 
sgRNA/Cas9/pTREX-
n plasmid (10μg) 
10μl nanopure 
H2O 
400μl (1x108/ml 
Epimastigotes) 
80μl pfr2 donor dna 
(15μg) 
30.5μl pfr2 donor dna 
(8μg)  
400μl (1x108/ml 
Epimastigotes) 
 
400μl (1x108/ml 
Epimastigotes) 
400μl (1x108/ml 
Epimastigotes) 
  
 
Pfr2 transfection Pfr2 transfection Control Control 
137μl donor dna (24.9μg) 106μl donor dna 
(18.1μg) 
10μl 
nanopure 
H2O 
350μl 
1x108cells/ml 
epimastigotes 
128μl sgRNA/Cas9/pTREX-
n plasmid (23.3μg) 
128μl 
sgRNA/Cas9/pTREX-
n plasmid (25.2μg) 
350μl 
1x108cells/ml 
epimastigotes  
350μl 1x108cells/ml 
epimastigotes 
350μl 1x108cells/ml 
epimastigotes   
 
Pfr5 transfection 
sgRNA/Cas9 plasmid 
control Control 
129μl donor dna (26.71μg) 
116μl 
sgRNA/Cas9/pTREX-n 
plasmid (26μg) 
400μl 
2.27x107cells/ml 
epimastigotes 
116μl sgRNA/Cas9/pTREX-n 
plasmid 
400μl 2.27x107cells/ml 
epimastigotes  
400μl 2.27x107cells/ml 
epimastigotes 
  
 
 
Table 5 Set up of the four cuvettes used during the first transfection protocol tested.   
Table 6 Set up of the four cuvettes used during the second transfection protocol tested. 
Table 7 Set up of the three cuvettes used during the third transfection protocol tested.   
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Figure 12 Illustration detailing how all the transfections from table 7 were diluted and 
plated 24 hours post transfection.  
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Transfection Confirmation 
 Integration of pfr2 specific sgRNA/Cas9/pTREX-n plasmid and donor DNA 
cassette, during implementation of transfection and antibiotic selection protocols two and 
four, was tested periodically after the antibiotic selection was started. Genomic DNA 
from possibly double resistant mutants was used to PCR amplify the sgRNA from the 
plasmid [pfr2 guide sequence forward primer and HX1 reverse primer (Table 1, Primers 
1 and 4)] and the donor DNA cassette insert [gene specific forward primer and 
puromycin resistance gene reverse primer (Table 1, Primers 10 and 9)]. Genomic DNA 
from second protocol was isolated using the Wizard SV genomic DNA purification 
system (Promega, ca# A2360) rather than the method described in the methods section. 
Only the sgRNA showed amplification at the expected size of 190bp (figure 13). PCR 
confirmation of integration was not done for the first protocol, third protocol, and pfr5 
transfects from the fourth protocol, due to the low number of viable parasites and the 
inability to obtain a sufficient amount of genomic DNA for analysis. 
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Figure 13 Representative agarose gel electrophoresis images showing the amplification of 
pfr2 sgRNA from genomic DNA of parasites transfected with pfr2 sgRNA/Cas9pTREX-n 
plasmid and donor DNA cassette. (A) From parasites transfected using the second 
transfection and antibiotic selection protocol. (B) From parasites transfected using the 
fourth transfection and antibiotic selection protocol. Expected size of 190bp. 
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CHAPTER V 
DISCUSSION 
 Within this study, we were able to create plasmid and DNA constructs for pfr2 
and pfr5 gene tagging, as well as confirm the incorporation of pfr2 specific 
sgRNA/Cas9/pTREX-n plasmid into the genome. In addition, we were able to rework 
and troubleshoot much of the protocol from Lander et al. (2016) to function within our 
lab. Much of the troubleshooting was with the bacterial transformation following ligation 
and with maintenance of viable epimastiogtes post transfection. While the bacterial 
transformation was successfully troubleshot through the testing and modification of 
several CaCl2 and electroporation protocols, the survivability and growth of 
epimastiogtes post transfection is still a work in progress. Throughout the different 
transformation and antibiotic selection, protocols tested a consistent problem was a lack 
of or stunted parasite growth. In some instances, such as some of the pfr2 transfected 
parasites from the second and fourth protocols, parasite clusters that contained parasites 
with normal flagellar movement could be seen, but these parasite clusters never grew to 
sizes seen with wild type T. cruzi. The pfr5 transfected parasites rarely showed signs of 
the clusters and often died off in greater numbers before the pfr2 transfected parasites. In 
addition to the lack of growth, PCR amplification of pfr2 donor DNA from genomic 
DNA never produced PCR product, even though there were viable parasites up to 6 plus 
weeks post transfection.  
The lack of integration or confirmation of integration could be due to variety of 
factors that have yet to be fully explored, although a few reason could be the inefficiency 
of the parasites to go through HDR, the length of the homologous arms (in the case of 
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pfr5) not being long enough for HDR in T. cruzi or, the cell debris present within the 
media limiting growth. In regard to the efficacy of the repair mechanism, when the DNA 
of the parasite is cut by the sgRNA/Cas9 complex the break will most often be repaired 
using NHEJ since this is often a less intensive process that does not require the use of a 
homologous sequence, thus limiting the likelihood that donor DNA will be used for 
repair. The length of the homologous arms for the pfr5 donor DNA cassette is the most 
probable reason as to why the pfr5 transfected parasites fared worse than the pfr2 
transfected parasites. The decision to try the smaller 30bp (compared to 100bp) 
homologous arms was spurred by a publication that utilized this arm length to tag genes 
with mNeonGreen, make null mutants using resistance genes and switch out fluorescent 
reporter proteins in T. cruzi (Costa et al., 2018). Although this publication was able to use 
a smaller arm length, our implementation of the 30bp homologous arms resulted in the 
pfr5 transfected parasites having visibly fewer numbers post-transfection than the pfr2 
transfected. In addition, those parasites often had decreased flagellar movement. These 
observations suggest that the length of the homology arms plays an important role in the 
likelihood of HDR. It is possible that for the length of our donor DNA cassette, longer 
homologous arms were necessary and the use of longer homology arms with the pfr2 
transfections may have contributed to their prolonged survival. In the weeks after 
transfection, a large portion of the parasites died, thus leaving a lot of cell debris in the 
media. When changing out the media in the few weeks following transfection, several 
centrifuge speeds were tested to see if this would limit the amount of debris that would be 
carried over. A lower centrifuge speed did seem to get rid of some of the debris but much 
of it remained. Another problem with the debris is that the parasite would often get suck 
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in the debris, leaving very few free-swimming parasites. The parasites did seem to be 
able to divide when stuck within the debris although the growth was limited.    
An additional factor that could explain the low number of parasites, but could also 
limit the use of this protocol, is the possibility that the gene tagging protocol is resulting 
in a fatal mutation. The PFR is a trilaminar structure composed of cytoskeletal filaments 
that come together to form one cohesive structure, that works to provide stability to the 
flagellum (Portman and Gull, 2010). The exact way in which the various proteins of the 
PFR interact and/or bind to one another is not fully understood, although knockout 
studies have been performed to investigate the importance of various PFR proteins in the 
overall function of the PFR. One such study knocked out two of the core proteins of the 
PFR, PFR1, and PFR2, by using CRISPR/Cas9 to insert an antibiotic resistance gene at 
the N-terminus of the genes (Lander et al., 2015). Knockouts of either protein resulted in 
an incomplete formation of the PFR, detachment of the axoneme from the cellular body, 
and a loss of motility (Lander et al., 2015). In essence, the disruption of pfr1 or pfr2 
resulted in a lethal mutation. The results of this study could be an indicator as to why our 
parasite populations were always so low. The insertion of the tag sequence at the C-
terminus of the genes, particularly pfr2, could have hindered the ability of the proteins to 
correctly incorporate into the PFR to some extent and resulted in a fatal mutation, similar 
to that of the study. Further testing needs to be done to determine if this is occurring or if 
there is another reason behind the low cell populations. If tagging of pfr genes is a lethal 
mutation, then this protocol may not be viable for PFR localization even though it has 
been successfully used in the localization of a flagellar calcium binding protein and 
acidocalcisome vacuolar proton pyrophosphatase in T. cruzi (Lander et al., 2016). 
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 As stated earlier there were changes made to the original Lander et al. (2016) 
protocol, with those changing including: reagents used for PCR and PCR product cleanup 
(i.e. Q5 high fidelity 2x master mix, Apex Taq RED master mix, Zymo gel DNA 
recovery kit, and DNA clean and concentrator kit), length of homology arms for donor 
DNA cassette (from 100bp to 30bp for pfr5 tagging), culture medium (Schneider’s 
complete media instead of liver infusion tryptose), electroporation conditions (1.3kV, 
100μs instead of 1.5kV, 25μF; the use of Tb-BSF instead of cytomix), and several aspects 
of the various protocols detailed in the methods and results sections. Some of these 
changes were done out of necessity (i.e. limited budget or supplies available; Q5 high 
fidelity 2x master mix, Apex Taq RED master mix, and Schneider’s complete media, 
electroporator settings) while others were done to test the viability of different methods 
(DNA clean and concentrator kit, length of homologous arms, and electroporation 
conditions). The implementation of the DNA clean and concentrator kit and the 
electroporation conditions resulted in some of the most positive differences when testing 
out all of the various methods. The clean and concentrator consistently allowed us to get 
higher DNA yield from our PCRs in comparison to the Zymo gel recovery kit, while the 
Tb-BSF resulted in less cell death immediately following electroporation in comparison 
to cytomix. The decision to use Tb-BSF rather than cytomix for the final round of 
transfections was spurred by a study done by Romagnoli et al. (2018), which aimed to 
improve CRISPR/Cas9 gene disruption in T. cruzi. Within this study, they tested out 
various electroporation solutions, including Tb-BSF and cytomix, and compared cell 
viability post-transfection. The results of these tests showed that cytomix was the worst 
performing, with ~15% viability 24 hours post-transfection, while Tb-BSF was one of the 
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best performing, with ~90% viability 24 hours post-transfection (Romagnoli et al., 2018). 
A similar difference in cell viability was seen within our final transfection and was most 
notable with the control cells, which had minimal cell death 24 hours post transfection, 
but could also be seen with the pfr2 and pf5 transfected cells, which has less cell debris 
than what was common with cytomix 24 hours post transfection. We were only able to 
test this buffer during a single round of transfection, but from what was seen during this 
transfection and the Romagnoli et al. (2018) publication it seems that this buffer is 
preferable for T. cruzi electroporation. While the change in electroporation buffer was 
driven by a literature search, the decrease in voltage used for electroporation was due to 
the limits of the electroporator used within our study. Through the various transfection 
protocols tested the electroporator was initially set to 1.5kV but it was unable to deliver 
this voltage because of arching, which can be due to the presence of air bubbles or high 
concentration of salts. Although we were not able to reach the voltage designated in the 
Lander et. al (2016), we were able to get close by decreasing the volume of plasmid and 
donor DNA added to the cuvette. A further decrease in volume may increase the charge 
that can be delivered and potentially have a slight impact on transfection efficiency.   
In order to move past the current hurdle of parasite viability and obtain gene 
tagged parasites, we are continuing to investigate ways to improve transfection 
efficiency, in addition to looking into other CRISPR protocols that have been developed 
with T. cruzi. Means by which to improve transfection efficiency could include, 
performing multiple transfections on the same cell population, which increases the 
likelihood that a parasite will integrate both the plasmid and the donor DNA, or using 
products that increase HDR likelihood, such as the IDT HDR enhancer (cat# 1081072). 
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Regarding other CRISPR protocols for T. cruzi, one protocol, presented in Romagnoli et 
al (2018), first established a stable cell line that expresses Cas9-GFP using the 
Cas9/pTREX-n plasmid and then transfected with transcribed sgRNA. This protocol was 
only used to test gene knockouts using gene specific sgRNA, but aspects of this protocol 
could be integrated into the current one to alleviate the requirement that two large 
constructs, the sgRNA/Cas9/pTREX-n plasmid and the donor DNA, must enter the cell 
during the same transfection in order for gene tagging to work. Another protocol 
presented in Soares Medeiros et al. (2017) took the approach of transfecting parasites 
with a Cas9/sgRNA protein complex (instead of a plasmid) assembled using Cas9 from S. 
aureus (smaller that the commonly used Cas9 from S. pyogenes) and donor DNA that 
contained only 2 HA epitopes flanked by 20bp homology arms. Three days post 
transfection these parasites were stained with anti-HA antibodies and put through a flow 
cytometer (Soares Medeiros et al., 2017). Those that were positive for the HA tag were 
examined under a microscope to look for protein localization (Soares Medeiros et al., 
2017). The implementation of a smaller endonuclease and donor DNA could greatly 
improve our transfection efficiency, while the use of flow cytometry would eliminate the 
need for antibiotic selection and would allow us to determine if our transfections were 
successful earlier.  In conclusion, the completion of the DNA constructs, as well as the 
troubleshooting of the procedures used, does provide a foundation for future students to 
utilize and improve upon this technique.  
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